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General introduction  
 
The root of Platycodon grandiflorum has been used as a traditional folk 
remedy for various respiratory diseases such as bronchitis, asthma, 
pulmonary tuberculosis and inflammation in East Asia (Takagi and Lee, 
1972). It was reported to contain carbohydrates (at least 90%), protein 
(2.4%), lipids (0.1%) and ash (1.5%) (Lee, 1973). Recently, it has been 
reported that the polysaccharides isolated from the root of Platycodon 
grandiflorum prevent obesity, hypecholesterolemia, hypertension, diabetes 
and hyperlipidemia (Kim et al., 1995; Han et al., 2001; Lee et al., 2011; Lim 
et al.,2011). The inulin-type polysaccharides from the roots of Platycodon 
grandiflorum demonstrated the selective immune-modulating effects on B 
cells and macrophages (Lee et al., 2008). More than 20 triterpenoid saponins 
have been found in the roots of Platycodon grandiflorum including 
platycosides (A, B, C, D, E and F), platycodins (A, D, D2 and D3), 
polygalacin (D and D2) and platyconic acid A (Kim et al., 2001; Dinda et al., 
2010). Triterpenoid saponins from Platycodon grandiflorum have been 
shown to exhibit a variety of pharmacological activities, such as anti-
inflammatory, anti-cancer, immune enhancing and hepatoprotective effects 
2 
(Kim et al., 2001; Khanal et al., 2009; Lee et al., 2008; Xie et al., 2009; Yu 
and Kim, 2010).  
The aim of the present studies was to assess protective effect of the 
standardized aqueous extract of Platycodon grandiflorum (PG) against liver 
injury using various chemical and surgical animal models. Moreover, 
additional studies were performed to confirm the protective effect of 
platycodin D, which is the most potent saponin in terms of its effect on 
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Chapter 1. Anti-hepatitis C viral activity and hepatoprotective effect of 
the standardized Platycodon grandiflorum extract on chemical-induced 
hepatotoxicity in mice 
 
Abstract 
The present study aims to evaluate the anti-hepatitis C virus (HCV) 
activity of standardized aqueous extract from Platycodon grandiflorum (PG) 
with HCV genotype 1b subgenomic replicon system and investigate its 
hepatoprotective activity on thioacetamide (TA) and carbon tetrachloride 
(CCl4)-induced acute liver damage in mice. PG produced significant 
hepatoprotective effects against TA and CCl4-induced acute hepatic injury by 
decreasing the activities of serum enzymes, nitric oxide and lipid 
peroxidation. Histopathological studies further substantiated the protective 
effect of PG. Furthermore, PG inhibited the HCV RNA replication with an 
EC50 value and selective index (CC50/EC50) of 2.82 µg/mL and above 35.46, 
respectively. However, digested PG using a simulated gastric juice showed 
poor protective effect against CCl4-induced hepatotoxicity in mice and 
decreased anti-HCV activity as compared to the intact PG. Although further 
studies are necessary, PG may be a beneficial agent for the management of 
acute hepatic injury and chronic HCV infection. 
6 
Introduction  
Polysaccharides obtained from many natural sources represent a 
structurally diverse class of macromolecules, and are known to affect a 
variety of biological responses. Recently, it has been reported that the 
polysaccharides isolated from the root of Platycodon grandiflorum prevent 
obesity, hypecholesterolemia, hypertension, diabetes, immune modulation 
and hyperlipidemia (Han et al., 2001; Kim et al., 1995; Lee et al., 2011; Lim 
et al.,2011). Triterpenoid saponins, such as platycodins (A, D, D2 and D3), 2 
and 3-O-acetyl polygalacin D2, platyconic acid and platycosides (A, B, C, D, 
E and F), were also found in the roots of the Platycodon grandiflorum 
(Dinda et al., 2010). These saponins are believed to have a wide range of 
health benefits and to prevent chemicals-induced hepatotoxicity (Lee et al., 
2001 and 2008). Although the beneficial effect of Platycodon graniflorum on 
acute hepatic failure using various chemical induced hepatic injury models 
has been widely studied, little is known about the preventative effect of 
Platycodon grandiflorum decoction on thioacetamide (TA) and carbon 
tetrachloride (CCl4)-induced acute hepatic injury in mice. In addition, 
information on its stability in the stomach has not been investigated and this 
information may be important to contribute to the development of 
Platycodon grandiflorum extract, which can later be directed to consumers 
with an increased knowledge of the content and biological activity of this 
7 
medicinal herb.  
The liver plays a central role in transforming and clearing xenobiotics, and 
is susceptible to their toxicity (Brattin et al., 1985). An animal model of 
fulminant hepatic failure induced by the TA and CCl4 has been described 
previously (Domitrovic et al., 2009; McCay et al., 1984; Recknagel et al., 
1989; Tunon et al., 2009; Wang et al., 2004). Within a short period of 
administration, TA is converted to thioacetamide sulfoxide (TASO) by the 
oxidase system. It is further metabolized by cytochrome P450 
monooxygenases to thioacetamide sulfone (TASO2), a highly reactive 
electrophilic metabolite. Covalent binding of this polar product to cellular 
macromolecules exerts hepatotoxicity, leading to generation of reactive 
oxygen species (ROS) (Chilakapati et al., 2005; Hunter et al., 1977; Kang et 
al., 2008). CCl4 is a potent hepatotoxicant and a single exposure to it can 
rapidly lead to severe centrizonal necrosis and steatosis (Brattin et al., 1985; 
Domitrovic et al., 2009). During its metabolization, an unstable 
trichloromethyl free radical (CCl3) is formed and rapidly converted to 
trichloromethyl peroxide (Recknagel et al., 1989; Domitrovic et al., 2009). 
These free radical result in the peroxidation of fatty acids found in the 
phospholipids making up the cell membranes. Lipid peroxide radicals, lipid 
hydroperoxides and lipid breakdown products develop in this process and 
8 
each constitutes an active oxidizing agent. Consequently, cell membrane 
structures and intracellular organelle membrane structures are completely 
broken down (Brattin et al., 1985; Recknagel et al., 1989; Domitrovic et al., 
2009). 
Hepatitis C virus (HCV) infection is a major healthcare problem around 
the world (Alter, 2007). HCV infection usually runs a chronic infection in an 
estimated 70% of HCV patients. Approximately 170 million subjects are 
chronically infected with HCV (Feld and Hoofnagle, 2005; Fried et al., 
2002). A chronic HCV infection leads to cirrhosis and hepatocellular 
carcinoma and causes 300,000 deaths per year (Alter, 2007). Current 
treatment is based on a combination of pegylated interferon (IFN)-α and 
ribavirin, which directly inhibits HCV replication and causes progressive 
infected cell clearance through intricate and only partly understood 
mechanisms (Fried et al., 2002; Feld and Hoofnagle, 2005). Among natural 
antiviral agents, recent investigations have reconsidered the interest of phyto-
polysaccharides, which act as potent inhibitors of different viruses (Ikeda et 
al., 2006; Seeff et al., 2008; Wagoner et al., 2010). 
In the present study, the standardized hot water extract from Platycodon 
grandiflorum (PG) was tested for its antiviral properties using a cell-based 
HCV subgenomic replicon system. We also investigated its protective effect 
9 
on chemical-induced acute hepatic injury in mice. 
 
Materials and methods 
Chemicals and reagents 
Thiobarbituric acid reactive substances (TBARS), glutathione (GSH), and 
nitric oxide (NO) assay kits were purchased from BioAssay Systems 
(Hayward, CA, USA). Serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), blood urine nitrogen (BUN) and creatinine (CRE) 
test kits were obtained from IDEXX Laboratories (Westbrook, ME, USA). 
The superoxide dismutase (SOD) assay kit was obtained from Cayman (Ann 
Arbor, MI, USA). CCl4, TA, Folin-Ciocalteu phenol reagent, 2,2-diphenyl-1-
picrylhydrazyl (DPPH) and other chemicals were purchased from Sigma 
Chemicals (St. Louis, MO, USA). Acetonitrile and methanol as High-
performance liquid chromatography (HPLC)-grade were obtained from 
Mallinckrodt Baker (Phillipsburg, NJ, USA). 
 
Preparation of PG 
The standardized Platycodon grandiflorum aqueous extract (PG) was 
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manufactured by SkyHerb Pharmaceuticals (Zhejiang, China) in accordance 
with good manufacturing practices (GMP). Briefly, the dried roots of 
Platycodon grandiflorum (100 g) were cut into slices and extracted in 
distilled water with occasional shaking at 60-90 °C for 6-10 h. The aqueous 
extract was then filtered, concentrated under reduced pressure in a rotary 
evaporator and spray-dried into powder (36 g). It has previously been 
reported that the aqueous extracts of the roots of Platycodon grandiflorum 
contain an inulin-type polyfructose, (1→2)-β-D-fructan2,3,13. It also 
includes deapio-platycoside E, platycoside E, deapio-platycodin D3, 
platycodin D3, deapio-platycodin D, platycodin D, polygalacin D, 3″-O-
acetyl polygalacin D, platycodin A and 2″-O-acetyl polygalacin D. PG was 
standardized in reference to platycodin D (at least 0.8%) using a validated 
HPLC-evaporative light scattering detector (ELSD) method. 
 
Gastric degradation simulation 
Simulated gastric juices were prepared by suspending pepsin (1 : 10,000, 
ICN) in sterile saline (0.5% w/v) to a final concentration of 3 mg/mL and 




HPLC analysis of PG was carried out as previously described (Kim et al., 
2007). In brief, HPLC analysis of PG was performed on a Younglin ACME 
9000 (Seoul, Korea) equipped with a Sedex 55 evaporative light scattering 
detector (ELSD; SEDERE, Alfortville, France). Sample separation was 
achieved in a Gemini C18 column (100 mm×4.6 mm, 3 µm particle size; 
Phenomenex, Torrance, CA, USA) with a precolum (C18, 3.5µm, 2×20 mm) 
at room temperature. The mobile phase consisted of 0.1% formic acid / 
methanol / acetonitrile (75: 5: 20, v/v/v; A) and 0.1% formic acid / methanol 
/ acetonitrile (70: 5: 25, v/v/v; B) and gradient runs programed as follows: 0-
10 min (0% B), 10-17 min (0-50% B), 25-34 min (50-80% B), 42-52 min 
(100% B) and then equilibration with 0% B for 10 min at a flow rate of 1 
mL/min. The injection volume was 20 µL. The ELSD was set to a probe 
temperature of 70°C, a gain of 7, and the nebulizer gas nitrogen adjusted to 
2.5 bar.  
 
Anti-HCV activity in the HCV replicon model of PG 
The plasmid pNNeo/3-5B replicon of Ikeda et al. (2002) contains the 
sequence of a similar HCV replicon in which almost all of the NS3-NS5B 
12 
sequence comprising the 3′cistron is derived from an infectious molecular 
clone of the genotype 1b virus, HCV-N (GenBank accession no. AF139594). 
It was kindly provided by Prof. Soon-bong Hwang (Ilsong Institute of Life 
Science, Hanllym University, Anyang, Korea). An expression vector 
harboring HCV replicon proceeded to in vitro transcription and the obtained 
HCV replicon was transfected into the Huh7 cells by electroporation. To 
select only those cells having the HCV replicon, Huh7 cells were cultured 
with Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% of fetal bovine serum, 1% nonessential amino acids, 
and 500 µg/mL of geneticin. 
HCV replicon-harboring cells were seeded at a low density of 1×104 cells 
per well in a 96-well plate and maintained at 37°C and 5% CO2. The next 
day, the culture medium was replaced with medium containing serially 
diluted compounds in the presence of 2% FBS and 0.1% DMSO. After the 
cells were treated for 72 h, total RNA was extracted using a CellAmp Direct 
RNA Prep Kit (Korea Biomedical, Seoul, Korea). The HCV RNA levels 
were quantified by a quantitative real-time polymerase chain reaction assay 
using an IQ5 real time PCR detection system (Bio-Rad, Hercules, CA, USA) 
with HCV-specific primers (5′-GACACTCCACCATAGATCACTC-3′and 5′-
CCCAACACTACTCGGCTAG-3′) and probe (5′-FAM-
13 
CCCAAATCTCCAGGCATTGAGCGG-3′BHQ-1). Results were normalized 
to glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH). Each data 
point represents the average of at least 3 replicates in cell culture. Relative 
HCV RNA reduction was assessed by comparing the level of HCV RNA in 
compound treated cells to control cells treated with 0.1% DMSO.  
 
Cytotoxicity of PG 
The cytotoxicity of PG on Huh7 cells was determined. Cell viability was 
then assessed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide colorimetric assay. The 50% cytotoxic concentration (CC50), 
defined as the compound concentration that inhibited proliferation of 
exponentially growing cells by 50%, was calculated.  
 
Polyphenolic content and DPPH radical scavenging activity 
The total phenolic content was determined according to the method 
described by Slinkard and Singleton (1977). The sample was accurately 
weighed and dissolved in a 100 mL brown volumetric flask with distilled 
water. The standard solution of gallic acid (0-0.06 mg/mL) was prepared. 
The standard and the sample (0.40 mL each) were mixed with the Folin-
14 
Ciocalteu phenol reagent (0.5 mL) and 20% of Na2CO3 (1.5 mL). The 
absorbance at 760 nm was measured 20 min after incubation at 30°C using 
an ultraviolet-visible spectrophotometer.  
The free radical scavenging activity of PG was measured using the stable 
radical DPPH (Blois, 1958). A solution of DPPH (0.1 mM) in ethanol was 
prepared, and 900 µL of this solution was added to 100 µL of PG solution at 
different concentrations (0.05-5 mg/mL). The resulting solution was 
thoroughly mixed by vortexing and left in the dark, and then the absorbance 
was measured at 517 nm at different times until the reaction reached a steady 
state. The scavenging activity was determined by comparing the absorbance 
with that of the blank. When the reaction reached a plateau, the IC50 value of 
PG was calculated from the results. 
 
Animals and treatments 
Male ICR mice (5-6 week, 32-36 g) were used for this study. They were 
obtained from OrinetBio (Sungnam, Korea) and acclimated for 1 week 
before experiments. Healthy ICR mice were randomly allocated into 5 
groups (n=6) for each model. For TA model, one group served as a control to 
orally receive distilled water. The others were orally administered with PG (0, 
15 
1, 5 and 10 mg/kg) for 3 consecutive days. For CCl4 model, one group 
served as a control to orally receive distilled water and the others were 
administered PG (0, 1 and 5 mg/kg bodyweight) and digested PG with 
simulated gastric juice (10 mg as PG/ kg bodyweight) for 3 consecutive days. 
At 3 h after the last treatment, both model mice were intraperitoneally 
injected with 200 mg/kg of TA (saline for control) or 50% of CCl4 (1 mL/kg 
in olive oil; olive oil for control). After 24 h of TA or CCl4 inmjection, mice 
were killed by cardiac puncture after being anesthetized lightly with carbon 
dioxide. Collected blood samples were separated by centrifuging at 800×g 
for 15 min and the serum samples were subjected to biochemical 
investigations. Liver samples from each mouse were removed for 
histopathological and biochemical examination. The experimental protocols 
were approved by the Institutional Animal Care and Use Committee of 
Chungnam National University (Daejeon, Korea). 
 
Serum and hepatic biochemical examination 
The serum ALT, AST, BUN and CRE activities were determined on a dry 
chemistry system, the Vettest 8008 blood chemistry analyzer (IDEXX 
Laboratories). The content of malondialdehyd (MDA), a terminal product of 
lipid peroxidation, was measured with the thiobarbituric acid reduction 
16 
method using a commercially available kit (Quatichrom TBARS assay kit, 
Bioassay Systems). The hepatic GSH levels were determined using the 
improved DTNB (5,5′-dithiobis-(2-nitrobenzoic acid)) method 
(QuantiChrom GSH Assay kit; BioAssay Systems). The hepatic SOD levels 
were also evaluated using the superoxide dismutase assay kit (Cayman). 
 
Histopathological examination 
The liver slices were made from a part of the left lobe and fixed 
immediately in a 10% buffered formalin phosphate solution, embedded in 
paraffin, and sectioned at 5 µm. The serial sections were stained with 
hematoxylin and eosin (H&E) to evaluate the portal inflammation, 
hepatocellular necrosis and Kupffer cell hyperplasia. To quantify the degree 
(%) of hepatic necrosis, liver H&E sections were digitally photographed, and 
the percentage of necrotic areas was quantified as the mean of 10 randomly 
selected fields within each slide. 
 
Statistical analysis 
Results were expressed as mean ± standard error (SE). The significances 
of differences among experimental groups were determined using one-way 
17 
analysis of variance (ANOVA) or the corresponding non-parametric Kruskal-
Wallis test, as required. Where significant effects were found, post-hoc 
analysis using Turkey’s multiple comparison test or the Mann-Whitney U-




On the basis of fingerprint analysis of PG, it contained a large group of 
oleanane-type triterpenoid saponins, such as deapioplatycoside E, 
platycoside E, platycodinD3, platycodin D2, platycodin D, platycodin A, 
polygalacin D, 3″-O-acetyl polygalacin D, 2″-O-acetyl platycodin D (Fig. 1). 
Among these triterpenoid saponins, platycodin D is the major and potent 
constituent of triterpenoid saponin found in the root of Platycodon 
grandiflorum. Thus, PG was standardized in reference to platycodin D (at 
least 0.8%) A number of other non-saponin chemical constituents have been 
identified from Platycodon grandiflourm, including α-spinasterol, α-
spinasteryl-β-glucoside, stigmasterol, inulin-type polyfructose, and pectin 
(Che, 1992; Oka et al., 1992). 
18 
 
Fig. 1. Representative HPLC chromatograms of triterpenoids from extract of Platycodon 
grandiflorum and PG. (A), PG; (B), simulated gastric digestion of PG with pepsin-HCl (pH 
2.0) for 2 h. The numbers indicate each platycoside: 1, deapio-platycoside E; 2, platycoside 
E; 3, platycodinD3; 4, deapio-platycodin D; 5, platycodin D; 6, polygalacin D; 7, 3″-O-
acetyl polygalacin D; 8, platycodin A; 9, 2″-O-acetyl polygalacin D.  
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Total phenol content and DPPH radical scavenging activity 
The DPPH free radical scavenging activity of PG is shown in Fig. 2 and 
the calculated EC50 of PG was 0.91 mg/mL. Simulated gastric digestion of 
PG with pepsin-HCl (pH 2.0) for 2 h did not show any difference of phenolic 
content, whereas DPPH radical scavenging activity was significantly 
decreased in gastric digestion of PG (p<0.05, Fig. 2). Triterpenoids in PG 
after 2 h of digestion with pepsin under acidic conditions were also slightly 
decreased to approximately 92.24±4.32% of intact PG, based on the relative 
amount of platydodin D. 
 
Fig. 2. Total phenolic content and DPPH free radical scavenging activity of PG. (A) total 
phenolic content of PG before and after gastric digestion with pepsin-HCl (pH 2.0) for 2 h at 
37°C. The total phenolic contents were expressed as mg of gallic acid equivalent (GAE) per 
g of PG. (B) changes in DPPH free radical scavenging activity of PG (500 µg/mL) before 
and after gastric digestion with pepsin-HCl (pH 2.0) for 2 h at 37°C. Vitamin C (10 µg/mL) 
served as a positive control for DPPH free radical scavenging activity. Values are expressed 
as means±SE. *p < 0.05, a significant difference in comparison with gastric digestion of PG 
(500 µg/mL) with pepsin-HCl (pH 2.0) for 2 h. 
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Anti-HCV activity of PG 
The anti-HCV activity of PG was evaluated in Huh7 cells harboring the 
HCV genotype 1b replicon. PG caused a dose-dependent inhibition of HCV 
RNA replication without affecting cell viability or cell growth. The 
calculated EC50 of PG was 2.82 µg/mL (Fig. 3). However, the anti-HCV 
activity of digested PG with simulated gastric juice significantly decreased 
(p<0.05). Cytotoxicity of PG on Huh7 cells was also studied. The CC50 
value of PG was above 100 µg/mL and the selective index (CC50/EC50) of 
PG in vitro was more than 35.46. 
Fig. 3. Suppressive effect of PG on HCV RNA replication. Huh7 cells harboring the HCV 
genotype 1b replicon were treated with different concentrations (1, 2, 5, 10 and 20 µg/mL) 
of PG (A) before and after simulated gastric digestion of PG (10 µg/mL) with pepsin-HCl 
(pH 2.0) for 2 h (B). Treatment with 0.1% DMSO served as a mock control for anti-HCV 
activity. Total RNA of PG treated Huh7 cells was extracted to quantify HCV RNA levels by 
RT-qPCR. Cytotoxicity was simultaneously evaluated by MTT assay. Values are expressed 
as means±SE for triplicate experiments. *p <0.05, a significant difference in comparison 
with gastric digestion of PG (10 µg/mL) with pepsin-HCl (pH 2.0) for 2 h. 
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Effect of PG on serum liver enzymes 
After TA injection, marked increases in the levels of ALT, AST, BUN and 
CRE were shown in TA alone treated mice (Table 1). This increase was 
attenuated in mice that received PG in a dose-dependent manner. Moreover, 
the group treated with 10 mg/kg of PG showed reduced liver enzyme and 
renal function marker (BUN and CRE) levels to a greater extent than the 
positive control group (p<0.05). 
In CCl4 model, the CCl4 alone treated group showed increased serum ALT 
and AST as compared to the negative control group (p<0.05, Fig. 4). The 
elevated levels of serum ALT and AST were reduced in the group treated 
with 5 mg/kg bodyweight of PG (p<0.05). Treatment with PG decreased 
ALT and AST levels in CCl4 treated mice in a dosedependent manner (Fig. 4). 
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Table 1. Effect of PG on serum biochemical parameters in TA-induced fulminant 
hepatic failure in mice  










control 97.3±21* 71.5±8.6* 106.8±9.0* 15.4±1.5* 0.3±0.09* 
TA alone 4308.3±246 8351.6±890 167.5±42.5 72.5±12.5 0.8±0.17 
TA+ PG   
(1 mg/kg) 3425.8±722 7465.0±700 166.2±9.4 57.5±17.5 0.6±0.11 
TA+ PG   
(5 mg/kg) 2912.5±435* 7275.0±1130 150.0±10.8 46.2±10.2* 0.5±0.06* 
TA+ PG  
(10 mg/kg) 2301.1±510* 6312.5±1351* 156.2±11.4 32.5±12.5* 0.4±0.05* 
Values are expressed as means ± SEM. The mice in the negative and positive control groups 
were orally given distilled water. The others were orally administered PG (1, 5, and 10 
mg/kg) for three consecutive days. At 3 h after the last oral administration, mice were 
intraperitoneally injected saline or 200 mg/kg of TA. * Significantly different compared with 
the positive control group (p < 0.05).
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Fig. 4. Effect of PG on liver function in CCl4-induced acute hepatic injury. Mice were given 
orally PG (0, 1 and 5 mg/kg bodyweight) once daily for 3 consecutive days prior to 
intraperitoneal injection of 50% CCl4 (1 mL/kg bodyweight in olive oil) or olive oil. Mice in 
the digested PG with a stimulated gastric juice treated group were given orally digested PG 
(10 mg/kg bodyweight) once daily for 3 consecutive days prior to intraperitoneal injection of 
50% CCl4 (1 mL/kg in olive oil). Values are expressed as means±SE (in surviving animals). 
ap<0.05, a significant difference in comparison with the control group. bp<0.05, a significant 




Hepatic levels of GSH, TBARS, NO and SOD 
In TA model, the liver homogenate from the TA alone treated group 
showed significantly reduced activities of GSH and SOD, whereas increased 
levels of NO and TBARS (Fig. 5). The hepatic TBARS level in the positive 
control group was significantly increased by 1.9-fold compared with the 
level in the negative control group after TA injection (p<0.05). PG attenuated 
the increased TBARS level in PG pretreated group at 5 and 10 mg/kg 
(p<0.05). The level of hepatic NO was remarkably decreased by PG 
pretreatment in dose-dependent manners, compared with the positive control 
group. Moreover, the significant decrease in hepatic GSH, which was 
observed in the positive control group as compared with the negative control 
group, was significantly reversed by PG pretreatment (p<0.05). 
As in TA model, similarly, CCl4 alone treated group showed significant 
reduced activities of GSH and SOD, whereas increased levels of NO and 
lipid peroxidation (Fig. 6). The administration of PG showed an increase in 
GSH and SOD levels with decreased levels of NO and lipid peroxidation 
(Fig. 6). However, for digested PG with stimulated gastric juice under acidic 
conditions for 2 h, the antioxidant activity was decreased if compared to 
intact PG (5 mg/kg) treated groups. 
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Fig. 5. Effect of PG on TBARS (A), NO (B), GSH (C) and SOD (D) content in the TA-
induced fulminant hepatic failure. The mice in the negative and positive control groups were 
orally given distilled water. The others were orally administered with PG (1, 5, and 10 
mg/kg) for three consecutive days. At 3 h after the last oral administration, mice were 
intraperitoneally injected saline or 200 mg/kg of TA. Values are expressed as means ± SEM. 




Fig. 6. Effect of PG on TBARS (A), NO (B), GSH (C) and SOD (D) content on CCl4-
induced acute hepatic injury. Mice were given orally PG (0, 1 and 5 mg/kg bodyweight) 
once daily for 3 consecutive days prior to intraperitoneal injection of 50% CCl4 (1 mL/kg 
bodyweight in olive oil) or olive oil. Mice in the digested PG with a stimulated gastric juice 
treated group were given orally digested PG (10 mg/kg bodyweight) once daily for 3 
consecutive days prior to intraperitoneal injection of 50% CCl4 (1 mL/kg bodyweight in 
olive oil). Values are expressed as means±SEM. ap<0.05, a significant difference in 
comparison with the control group. bp<0.05, a significant difference in comparison with the 




The livers from the negative control group in both TA and CCl4 models 
had normal hepatic cells with well- preserved cytoplasm, a prominent 
nucleus, a nucleolus and visible central veins (Fig. 7 and 8).  
The TA alone treated mice showed severe hepatic injury characterized by 
centrilobular necrosis, periportal hepatocytic vacoulation and infiltration of 
inflammatory cells (Fig. 7). Most of the parenchyma of the liver was 
destroyed in this group of mice, resulting in hepatic failure. Confluent 
submassive necrosis was noted around the central vein in positive control 
group mice. Also, numerous neutrophil infiltrations were seen adjacent to 
necrotic areas. The lower dose of PG (1 mg/kg) did not prevent the toxic 
effect of TA, with large necrotic areas still present. The other doses of PG (5 
and 10 mg/kg) produced a more or less normal lobular pattern with a mild 
degree of hepatic injury. Scattered spotty necrosis was found, and some 
inflammatory cells surrounded spotty necrotic foci in mice treated with 5 and 
10 mg/kg of PG (Fig. 7). The necrotic area was significantly reduced in PG-
treated mice in a dose-dependent manner compared to the positive control 
group mice (Fig. 7). 
In CCl4 model, CCl4 alone treated mice showed extensive, mainly 
pericentral necrosis with loss of hepatic architecture, vacuolar fatty change 
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and mild inflammatory cell infiltration comprised predominantly of 
mononuclear cells and macrophages (Fig. 8).The lower dose of PG (1 mg/kg) 
did not prevent the toxic effect of CCl4 with large necrotic areas still present. 
However, the high dose of PG (5 mg/kg) showed a more or less normal 




Fig. 7. The histopathological changes in the liver stained with hematoxyline and eosin in the 
TA-induced hepatotoxicity (×200). The mice in the negative and positive control groups 
were orally given distilled water. The others were orally administered with PG (1, 5, and 10 
mg/kg) for three consecutive days. At 3 h after the last oral administration, mice were 
intraperitoneally injected saline or 200 mg/kg of TA. In the positive control mice, 
widespread destruction of the liver architecture was characterized by massive necrosis 
around the central vein and hemorrhage as well as infiltration of inflammatory cells adjacent 
to necrotic areas. In contrast, the group of mice treated with TA+10 mg/kg of PG displayed 
only a mild scattered spotty necrosis and inflammation. (A) Negative control group, (B) 
positive control group, (C) TA+1 mg/kg of PG group, (D) TA+5 mg/kg of PG group, (E) 




Fig. 8. The histopathological changes in liver stained with hematoxyline & eosin in CCl4-
induced hepatotoxicity (×200). Mice were given orally PG (0, 1 and 5 mg/kg bodyweight) 
once daily for 3 consecutive days prior to intraperitoneal injection of 50% CCl4 (1 mL/kg 
bodyweight in olive oil) or olive oil. Mice in the digested PG with a stimulated gastric juice 
treated group were given orally digested PG (10 mg/kg bodyweight) once daily for 3 
consecutive days prior to intraperitoneal injection of 50% CCl4 (1 mL/kg in olive oil). A, 
non-treated negative control; B, CCl4 alone treated group; C, CCl4+1 mg/kg of PG treated 





TA and CCl4 is a centrilobular hepatotoxicant, widely used as a model 
compound to induce acute and chronic liver diseases (Kang et al., 2008; Lee 
et al., 2008). Both chemicals bioactivated by hepatic microsomal CYP2E1 to 
produces hepatotoxic metabolites (Brattin et al., 1985; Brautbar and 
Williams, 2002; Kang et al., 2008; Ledda-Columbano et al., 1991). The 
covalent binding of the free radical to the cell proteins is considered to be the 
initial step in a chain of events that eventually lead to cell necrosis 
(Domitrovic et al., 2009; Kang et al., 2008). The results of the present study 
showed that chemical injection caused severe acute liver damage in mice, 
demonstrated by remarkable elevation of serum AST and ALT levels. The 
increased serum levels of AST and ALT are attributed to the damaged 
structural integrity of the liver.  
CYP2E1 metabolizes a large number of low-molecular-weight compounds, 
many of which are industrial solvents, chemical additives and drugs (Lieber, 
1997; Tanaka et al., 2000). An inhibition of CYP2E1 was associated with a 
decrease in toxicity induced by some chemicals, such as acetaminophen, 
benzene, CCl4 and chloroform (Lee et al., 1996; Tanaka et al., 2000). In 
previous studies, a crude saponin extract from Platycodon grandiflorum 
resulted in a significant decrease in the CYP2E1-dependent hydroxylation of 
32 
aniline and showed a hepatoprotective effects on CCl4-induced hepatic injury 
in mice (Lee et al., 2008). Thus, these results suggest that PG would 
attenuate the chemical-induced hepatic injury in mice by suppression of 
CYP2E1 and the same evidence has been reported by Kang et al. (2008). In 
addition, this assumption was also confirmed by histological observation. 
Perivenous cells contained a higher level of CYP2E1 compared to periportal 
cells, which reflected zonal differences toxicity (Lee et al., 1996; Tanaka et 
al., 2000). In the histopathogical examination, perivenous cells were much 
more severely damaged than periportal cells in positive control group mice, 
whereas the pretreatment with PG produced only a very mild degree of liver 
injury in a dose-dependent manner. 
GSH is the major non-enzymatic antioxidant and regulator of intracellular 
redox homeostasis, ubiquitously present in all cell types (Valko et al., 2007). 
The detoxification mechanism in chemical-induced hepatotoxicity involves 
GSH conjugation of the free radical (Brattin et al., 1985; Brautbar and 
Williams, 2002). It was reported that, administration of TA and CCl4 leads to 
a significant decrease in the glutathione level (Akhtar and Sheikh, 2013; 
Kwak et al., 2011). In addition, lipid peroxidation has been implicated in the 
pathogenesis of hepatic injury by the free radical derivatives and is 
responsible for cell membrane damage and the consequent release of marker 
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enzymes of hepatotoxicity (McCay et al., 1984; Domitrovic et al., 2009). In 
this study, pretreatment with PG prior to chemical-induced hepatic injury 
inhibited lipid peroxidation and reduced chemical-induced hepatic GSH 
depletion, as well as restoring hepatic Cu/Zn SOD activities in the liver. In 
addition, administration of PG prevented chemical-induced elevation of lipid 
peroxidation in a dosedependent manner, indicating its hepatoprotective 
effect. A sufficient regenerative response of PG by reducing the intensity of 
liver damage could be also expected.  
The current standard care for patients with chronic hepatitis C is 
combination therapy with pegylated IFN-α and ribavirin (Alter, 2007; Feld 
and Hoofnagle, 2005; Fried et al., 2002). It is effective in approximately 80% 
of patients with HCV genotype 2 or 3 infection, but less than 50% of patients 
with HCV genotype 1, by far the most frequent HCV genotype worldwide 
(Feld and Hoofnagle, 2005; Fried et al., 2002). In addition, the combination 
therapy is prolonged, costly, and may be associated with adverse effects that 
are difficult for many patients to tolerate (Fried et al., 2002). Thus, more 
effective, more tolerable, and/or more tailored therapies are required. 
Numerous studies recently showed that plant extracts exhibit an inhibitory 
effect on HCV enzyme and replication and they have demonstrated their 
utility in eradicating chronic hepatitis C through a multitude of 
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hepatoprotective functions in initial trials (Ikeda et al., 2006; Lee et al., 2011; 
Seeff et al., 2008; Wagoner et al., 2010; Zuo et al., 2007). Ma et al. (2002) 
reported that 27 of 44 medicinal herbs showed potent or moderate antiviral 
activities against respiratory syncytical virus (RSV). Among them, 
Platycodon grandiflorum extract exhibited an inhibitory effect against RSV 
with an IC50 value of 44.1 mg/mL an SI index of 8.0 (Ma et al., 2002). In the 
present study, we showed that PG strongly inhibited HCV genotype 1b 
replicon replication in Huh7 cells with an EC50 of 2.82 µg/mL and an SI 
index of >35.46, although the detailed mechanism has not been clearly 
defined. PG may be considered as a potential source of new bioactive 
compounds against HCV infection. 
There is still debate about the stability and absorption of plant-derived 
compounds comprising a wide range of bioactive constituents under 
gastrointestinal conditions. Inulin is a polysaccharide with β (2-1) linkages 
by which D-fructose is polymerized. Inulin is widely distributed throughout 
the plant kingdom and exists as a reserve substance in the tuber or tuberous 
roots of plants including Platycodon grandiflorum (Che, 1992; Oka et al., 
1992). Plant-origin inulin is resistant to hydrolysis by pancreatic amylase and 
saccharidase in the upper gastrointestinal tract and it reaches the large 
intestine unabsorbed and is utilized as a carbohydrate substrate for the 
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growth of indigenous bifidobacteria (Che, 1992; Oka et al., 1992). However, 
from many other studies on the degradation and metabolization of β-
glycosides of plant origin, it is known that the metabolization proceeds 
mainly via degradation processes already occurring in the gastrointestinal 
tract (Tawab et al., 2003). Moreover, Shimizu et al. reported that 
saikosaponins in Bupleurum species converted into their corresponding 
structural isomers of diene derivatives with acidic treatment or in gastric 
juice with low pH (Shimizu et al., 1985). Under acidic conditions, 
ginsenoside Re was mainly hydrolyzed to yield Rg2 and then ginsenoside 
Rg2 was transformed to 20(R)-Rg2 by epimerization, or changed to 
ginsenoside F4 and Rg6 via a dehydration reaction (Kong et al., 2009). In the 
present study, the treatment group with digested PG using a simulated gastric 
juice showed poor protective activity against CCl4-induced hepatotoxicity in 
mice and anti-HCV activity in HCV genotype 1b subgenomic replicon RNA 
containing Huh7 cells as compared to the PG. On the basis of these results, 
active ingredients of PG having the anti-HCV and hepatoprotective activity 
may be not stable in human gastric juice. Thus, PG for clinical use in humans 
may require a specific drug delivery system such as an enteric coated tablet 
formulation to minimize the degradation of its active ingredient by low 
gastric pH and to improve its bioavailability.  
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In conclusion, PG attenuates the chemical-induced acute hepatotoxicity in 
mice and inhibits HCV RNA replication in Huh7 cells harboring the HCV 
genotype 1b replicon. Although further studies are necessary, PG may be a 
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Chapter 2. Protective effect of the standardized aqueous extract from 




The root of Platycodon grandiflorum (Jacq.) A. DC. (Campanulaceae) has 
been widely studied for its hepatoprotective effects against various 
hepatotoxicants. The present study evaluated the protective effect of the 
standardized aqueous extract of Platycodon grandiflorum (PG) on acute and 
chronic cholestasis-induced hepatic injury. For shot-term bile duct ligation 
(BDL) model, the mice were allocated into five groups as follows: Sham-
operated, BDL alone, and BDL with PG (1, 5, and 10 mg/kg) treated group. 
PG was given for 3 consecutive days before BDL operation and sacrificed 
post-24 h of BDL. For long-term BDL model, the rats were divided into four 
groups as follows: Sham-operated, bile duct ligation (BDL) alone, and BDL 
with PG (10 and 50 mg/kg) treated group. PG was given for consecutive 28 
days after BDL operation. Both in short- and long-term BDL model, 
increased serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) in BDL alone group were decreased in PG treated 
group in a dose-dependent manner. Especially in short-term BDL model, the 
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10 mg/kg of PG-treated mice showed a 77% decrease of ALT and 56% of 
AST as compared with BDL alone. Decreased antioxidant enzyme, 
glutathione and superoxide dismutase, levels in BDL alone group were 
elevated in PG-treated groups. PG treatment also attenuated 
malondialdehyde and nitric oxide levels as compared with BDL alone. In 
addition, in the long-term BDL model, PG treatment significantly reduced 
the serum level of fibrogenic cytokine, TGF-b1. Histopathological studies 
further substantiated the protective effect of PG on long-term BDL-induced 
hepatic fibrosis in rat. PG may have beneficial effects not only on hepatic 
injury in acute cholestasis but also on hepatic fibrosis development in 




Biliary obstruction causes acute hepatocellular injury and leads to 
progressive fibrogenesis. It is also characterized by portal tract expansion, 
leukocyte infiltration, bile duct and septal proliferation, liver fibrosis and 
eventually cirrhosis. Although the pathogenesis of cholestatic liver disease is 
uncertain, several studies reported that free radicals may play a role in 
cholestatic liver injury (Montilla et al., 2001; Pastor et al., 1997). Bile acids 
enhanced the release of free radicals from activated polymorphonuclear and 
inflammatory cells in cholestatic liver lesions (Dahm et al., 1988). 
Furthermore, accumulated lipophilic bile acid during cholestasis impairs the 
activity of the electron transport chain in the liver mitochondria and reduces 
its antioxidant capacity (Dueland et al., 1991). Cholestasis has been shown to 
stimulate the expression of collagen gene transcripts (Lee et al., 1995; Lyons 
and Schwarz, 1984; Shimizu et al., 1999). Antioxidants have been shown to 
block stellate cell activation via type I collagen in hepatic fibrogenesis (Lee 
et al., 1995). Endogenous antioxidant defense mechanisms could play a 
central role in preventing extensive injury in cholestatic livers 
(Neuschwander-Tetri et al., 1996). 
The key pathological feature of hepatic fibrosis is the accumulation of 
extracellular matrix protein. It is well known that the fibrogenic cytokine 
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transforming growth factor-beta (TGF-β) plays a pivotal role in the 
development of hepatic fibrosis and cirrhosis through its stimulatory effect 
on matrix protein generation and its inhibitory effect on matrix protein 
removal (Friedman, 2000; Gressner et al., 2002). Therefore, an approach 
involving the inhibition of TGF-b1, a key member of the TGF-b superfamily, 
has been used in several therapeutic approaches to prevent hepatic fibrosis. 
However, there is no clinically effective treatment for liver fibrosis, and an 
effective therapeutic approach against the development of hepatic fibrosis is 
needed (Breitkopf et al., 2005). 
Recently, a report described that Sho-saiko-to, the most popular herbal 
medicine for the treatment of chronic liver disease in China and Japan, and 
silymarin, a hepatoprotectant with anti-hepatitis C virus (HCV) activity, 
significantly reduced the expression of TGF-b1, and platelet-derived growth 
factor inhibited hematopoietic stem cell (HSC) proliferation and activation in 
a bile duct ligation (BDL) model of cirrhosis (Chen et al., 2005; Jia et al., 
2001). Herbal therapies and products derived from natural compounds such 
as silymarin and Sho-saiko-to may well prove to be of use as adjunctive 
measures in the care of patients with HCV, but there have not yet been any 
adequately designed clinical trials to support this assumption (Teixeira et al., 
2007; Wagoner et al., 2010). 
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Triterpenoid saponins in the roots of the Platycodon grandiflorum are 
believed to prevent chemically induced hepatotoxicity (Lee et al., 2004 and 
2008). In our previous study, a standardized aqueous extract of Platycodon 
grandiflorum attenuated thioacetamide-induced fulminant hepatic failure in 
mice (Lim et al., 2011). Furthermore, the extract attenuated carbon 
tetrachloride (CCl4)-induced acute hepatotoxicity in mice and inhibited HCV 
RNA replication in Huh7 cells harboring the HCV genotype 1b replicon 
(Kim et al., 2011). Although the beneficial effect of Platycodon 
grandiflorumon acute hepatic failure has been widely studied using various 
chemically induced hepatic injury models, little is known about its ability to 
prevent hepatic fibrosis in BDL-induced cholestasis. Cholestasis is a 
common pathological condition that can be reproduced in rodents by surgical 
ligation of the common bile duct. 
The aim of the current study was to investigate the beneficial effects of the 
standardized Platycodon grandiflorum aqueous extract (PG) on BDL-
induced oxidative stress and hepatic fibrosis.  
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Materials and methods 
Chemicals and reagents 
Assay kits for thiobarbituric acid reactive substances (TBARS), 
glutathione (GSH) and nitric oxide (NO) were purchased from BioAssay 
Systems (Hayward, California, USA). The assay kit for superoxide 
dismutase (SOD) was obtained from Cayman Chemical (Ann Arbor, 
Michigan, USA). Test kits for serum alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), blood urea nitrogen (BUN) and total 
bilirubin (TBIL) were obtained from IDEXX (Westbrook, Maine, USA). 
TGF-b1 enzyme-linked immunosorbent assay (ELISA) kit was purchased 
from R&D systems (Minneapolis, Minnesota, USA). Other chemicals were 
obtained from Sigma chemicals (St Louis, Missouri, USA). High-
performance liquid chromatography (HPLC)-grade acetonitrile and methanol 
were obtained from Mallinckrodt Baker (Phillipsburg, New Jersey, USA).  
The standardized Platycodon grandiflorum aqueous extract (PG) was 
manufactured from SkyHerb Pharmaceuticals (Zhejiang, China) in 
accordance with good manufacturing practices. PG was standardized with 
reference to its platycodin D content (at least 0.8%) using a validated HPLC 
assay as described previously (Kim et al., 2007). 
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Animals and treatments 
Male Crl:CD1(ICR) mice (5-6 weeks; 32-36 g) and Sprague-Dawley (SD) 
rats (7-8 week; 250-300 g) were used for short- and long-term BDL study, 
respectively. They were obtained from Orient Bio (Seongnam, Korea) and 
acclimated for 1 week before experiments. They were housed under standard 
laboratory conditions (12 h light/dark cycle, 22-23°C) with standard mouse 
food pellet and water ad libitum. For short-term BDL study, mice were 
randomly allocated into 5 groups as follows: Group 1 (sham-operated, n = 5), 
Group 2 (BDL alone, n = 5), Group 3 (BDL and 1 mg/kg of PG treated, n = 
5), Group 4 (BDL and 5 mg/kg of PG treated, n = 5), and Group 5 (BDL and 
10 mg/kg of PG treated, n = 5). The sham-operated group and BDL alone 
group were orally administered distilled water, and the others were orally 
administered with PG (1, 5, and 10 mg/kg) for 3 consecutive days before 
BDL operation. At 3 h after the last treatment, common BDL was performed 
under anesthesia with intraperitoneal injection of zolazepam and tiletamine 
combination (Zoletil 50®, Virbac, Carros, France). After midline laparotomy, 
the duodenum was retracted, and common bile duct was carefully double 
ligated with a 6-0 nylon suture and dissected. Sham-operated mice received 
an identical laparotomy and isolation of the common bile duct without 
ligation. After 24 h of BDL, mice were sacrificed by cardiac puncture under 
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CO2 anesthesia.  
For long-term model, rats were randomly allocated into 4 groups as 
follows: Group 1 (sham-operated, n = 6), Group 2 (BDL alone, n = 6), Group 
3 (BDL and 10 mg/kg of PG treated, n = 6), and Group 4 (BDL and 50 
mg/kg of PG treated, n = 6). After anesthetization, the common bile duct was 
ligated using double ligatures with 4-0 silk in all group except for sham-
operated group. After surgery, BDL rats orally received distilled water or PG 
(10 and 50 mg/kg/day) for 28 consecutive days. PG was dissolved in distilled 
water. Sham-operated rats (n = 6) were also operated by making an 
abdominal incision without a ligation and were given distilled water orally 
for 4 weeks. Twenty eight days after the BDL operation, the rats were killed 
by cardiac puncture after being anesthetized lightly with carbon dioxide. 
Blood samples were collected and serum was separated by centrifuging at 
800 g for 15 min, and the serum samples were subjected to biochemical 
investigations. Liver samples from each mouse were taken for 
histopathological and biochemical examinations. Left lobes of liver were 
fixed immediately with 10% buffered formalin phosphate solution. Serum 
samples and other parts of livers were stored at -70°C until analysis. The 
experimental protocols were approved by the Institutional Animal Care and 
Use Committee of Chungnam National University (Daejeon, Korea). 
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Serum biochemical examination 
The serum levels of ALT, AST, BUN and TBIL were determined using a 
dry chemistry system, VetTest 8008 blood chemistry analyzer (IDEXX, 
Westbrook, Maine, USA). 
 
Oxidant and antioxidant parameters 
The level of SOD was measured by using the tetrazolium salt assay 
(Superoxide Dismutase Assay Kit, Cayman Chemical Company, Ann Arbor, 
MI, USA). The content of malondialdehyde, a terminal product of lipid 
peroxidation, was measured with the thiobarbituric acid reduction method 
using a commercially available kit (QuatiChrom TBARS Assay kit). The 
hepatic GSH level was determined using the improved DTNB (5,5’-
dithiobis-[2-nitrobenzoic acid]) method (QuantiChrom GSH Assay kit). NO 
was measured by improved Griess method (QuantiChrom NO Assay kit). 
 
Measurement of plasma TGF-β1 levels 
Plasma TGF-β1 levels were measured using an ELISA kit (R&D systems) 
according to the manufacturer’s guidelines.  
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Histopathological examination 
Liver slices were obtained from a part of the left lobe and fixed 
immediately in a 10% buffered formalin phosphate solution, embedded in 
paraffin and cut into 5 μm sections. Four random samples of each liver 
sample were stained with hematoxylin and eosin (H&E). Additionally, 
Masson’s trichrome staining was performed to facilitate the evaluation of 
periportal fibrotic bands. The degree of fibrosis was scored according to a 
modified histological activity index (HAI) (Ishak et al., 1995; Knodell et al., 
1981), which included portal inflammation, focal necrosis, confluent 
necrosis, piecemeal necrosis, apoptosis, focal inflammation and fibrosis. The 
number of biliary canals in five portal sites for each section was also noted. 
The samples were examined without prior knowledge of the clinical 
information and biochemical results. 
 
Statistical analysis 
Results were expressed as mean ± SEM. The significance of the 
differences among the experimental groups was determined using one-way 
analysis of variance or the corresponding nonparametric (Kruskal-Wallis) 
test, as required. Where significant effects were found, post hoc analysis was 
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performed using Tukey’s multiple comparison test or Mann-Whitney U test, 
and p<0.05 was considered statistically significant. 
 
Results 
Assessment of serum hepatic enzyme activities  
In short-term BDL study, the levels of serum ALT and AST in the BDL 
alone group significantly increased to 395.2 ± 90.0 and 266.0 ± 45.6 Unit/L 
compared with the sham-operated group (Fig. 1; p<0.05). However, PG (1, 5, 
and 10 mg/kg) pretreatment dose-dependently attenuated these BDL-induced 
elevations in serum ALT and AST levels up to 77% and 56%, respectively 
(Fig. 1). In addition, in long-term BDL study, liver injury was assessed by 
determining the serum levels of liver enzymes including ALT, AST, CRE and 
TBIL (Table 1). As shown in Table 1, the serum levels of AST, ALT, CRE 
and TBIL were significantly higher in BDL rats than in sham-operated rats 
(p<0.05) and PG treatment at a dose of 50 mg/kg to the BDL group reduced 




Fig. 1. Effect of PG on liver function in the bile duct ligation (BDL)-induced acute hepatic 
injury. Mice were given orally PG (0, 1, 5, and 10 mg/kg) once daily for 3 consecutive days 
prior to BDL. Values are expressed as means ± standard error (SEM). *p < 0.05, a 
significant difference in comparison with the positive control group. 
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Table 1. Effect of PG on serum biochemical parameters in BDL-induced cholestasis in rats. 
Groups  ALT (U/L)  AST (U/L)  AST/ALT ratio BUN (mg/dL)  TBIL (mg/dL) 
Sham-operated 65.50 + 7.6a  60.75 + 9.5a 0.93 + 0.09a  10.75 + 0.48a  0.52 + 0.05a 
BDL alone 112.00 + 5.3b  541.75 + 94.0b 4.75 + 0.65b  12.25 + 0.25b 7.25 + 0.64b 
BDL + PG (10 mg /kg)  116.50 + 13.6b 540.50 + 92.9b 4.57 + 0.35b  11.75 + 0.48b  5.63 + 0.34b 
BDL + PG (50 mg /kg) 89.33 + 4.6a,b  315.33 + 25.8a,b 3.52 + 0.17a,b 10.25 + 0.85  3.48 + 0.57a,b 
ALT: alanine aminotransferase; BDL: bile duct ligation; AST: aspartate aminotransferase; BUN: blood urea nitrogen; TBIL: total bilirubin. 
Values are expressed as means + SEM (in survival animals). After BDL operation, the rats in PG-treated groups were orally given PG (0, 10 
and 50 mg/kg) once a day for 4 weeks. The sham-operated groups were orally given the same volume of saline as the BDLtreated animals that 
received PG. ap < 0.05, a significant difference when compared with the group treated with BDL alone. bp < 0.05, a significant difference 
when compared with the sham-operated group.
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Effect of PG on GSH, SOD, TBARS, NO values 
To evaluate the possible effects of PG on oxidative stress status, lipid 
peroxidation products, GSH and SOD, were measured in liver homogenates. 
In short-term BDL study, the BDL alone group, significantly reduced 
activities of GSH and SOD were shown, whereas the levels of NO and 
TBARS were increased as compared with the sham-operated group (Fig. 3; 
p<0.05). Decreased GSH values by BDL were increased to 5.6 ± 0.94, 5.9 ± 
1.36, and 6.7 ± 0.17 nmole/mg of protein in the PG-treated group at 1, 5 and 
10 mg/kg, respectively. Similarly, SOD levels were also increased in the PG-
treated group in a dose-dependent fashion. The level of hepatic NO was 
remarkably decreased, ranging from 32 to 50%, by PG pretreatment. PG also 
attenuated the increased TBARS level in PG-treated group. As in short-term 
study, long-term BDL group showed significantly reduced GSH and SOD 
activity, together with increased levels of NO and TBARS in the group 
treated with BDL alone (Fig. 4). The hepatic TBARS level in the positive 
control group was significantly increased by 1.9-fold than that in the sham-
operated group (p<0.05). PG (50 mg/kg) attenuated the increased TBARS 
level in the BDL group (p<0.05). Hepatic NO levels remarkably decreased 
by PG treatment and PG also significantly ameliorated the significant 
decrease in hepatic GSH levels, which were observed in the group treated 
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with BDL alone (p<0.05). 
 
 
Fig. 3. Effect of PG on the hepatic GSH (A), SOD (B), lipid peroxidation (C) and NO (D) 
content in the bile duct ligation (BDL)-induced acute hepatic injury. Mice were given orally 
PG (0, 1, 5 and 10 mg/kg) once daily for 3 consecutive days prior to BDL. Values are 
expressed as means ± SEM. *p<0.05, a significant difference in comparison with the 




Fig. 4. Effect of PG on TBARS (A), NO (B), GSH (C) and SOD (D) content in the BDL-
induced cholestasis. After BDL operation, the rats in PG-treated groups were orally given 
PG at 0, 10 and 50 mg/kg body weight/day for 4 weeks. The sham-operated groups were 
orally given with the same volume of saline as the BDL-treated animals that received PG. 
Values are expressed as mean ± SEM. ap < 0.05, a significant difference when compared 
with the sham-operated group. bp < 0.05, a significant difference when compared with the 
group treated with BDL alone. TBARS: thiobarbituric acid reactive substances; NO: nitric 




In short-term study, sham-operated animals, there were no microscopic 
structural changes of liver from normal hepatic architecture (Fig. 5). The 
liver from the BDL alone group showed significant histopathological 
alteration of liver, such as mild ductal proliferation, polymorphic nucleus, 
hepatocyte necrosis, and inflammatory cell infiltration. In the low dose, PG 
(1 mg/kg) did not reduce the BDLinduced histopathlogical alteration, with 
mild ductal proliferation and inflammatory cell infiltration still present. The 
higher dose PG (5 and 10 mg/kg) treated groups showed much less necrosis 
of hepatocyte and infiltration of inflammatory cell than the BDL alone group. 
The HAI scores for long-term BDL liver of the different experimental 
groups are summarized in Table 2. The livers of the animals in the sham-
operated group had normal hepatic cells with well-preserved cytoplasm, a 
prominent nucleus, a nucleolus and visible central veins. In contrast, the 
livers collected from BDL-operated rats showed typical histological changes, 
which were characterized by bridge fibrosis formation in the portal area 
prominent ductular proliferation, edema and mild-to-moderate 
polymorphonuclear leukocyte and lymphocyte infiltration in the periportal 
region (Fig. 6). The long-term BDL rats that were treated with PG (50 mg/kg) 
had markedly reduced histological collagen accumulation, ductular 
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proliferation, edema and inflammation than did the group treated with BDL 
alone (Fig. 6). 
 
 
Fig. 5. Histopathological changes of the liver stained with hematoxyline and eosin on the 
bile duct ligation (BDL)-induced liver injury (×100). Mice were given orally PG (0, 1, 5, 
and 10 mg/kg) once daily for 3 consecutive days prior to BDL. (A) nontreated sham-
operated group; (B) nontreated BDL group; (C) PG (1 mg/kg) treated BDL group; (D) PG (5 
mg/kg) treated BDL group; (E) PG (10 mg/kg) treated BDL group. Arrows indicate the bile 
duct proliferation and hepatocyte necrosis. 
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Table 2. Scores for necor inflammation (focal necrosis, confluent necrosis, piecemeal necrosis, focal and portal inflammation and 
apoptosis) and fibrosis using modified HAI grading system. 
Groups Inflammation Fibrosis Number of biliary canals 
Sham-operated 0.75 + 0.48a 0.00 + 0.00a 36.75 + 3.75a 
BDL alone 10.75 + 1.25b 4.00 + 0.41b 352.00 + 38.08b 
BDL + PG (10 mg /kg) 9.50 + 0.96b 3.75 + 0.48b 322.75 + 40.38b 
BDL + PG (50 mg /kg) 6.00 + 0.91a,b 2.00 + 0.41a,b 268.50 + 22.51 
BDL: bile duct ligation; HAI: histological activity index. Values are expressed as means ± SEM (in survival animals). After BDL operation, 
the rats in PG-treated groups were orally given PG at 0, 10 and 50 mg/kg body weight/day for 4 weeks. The sham-operated groups were orally 
given the same volume of saline as the BDL-treated animals that received PG. ap < 0.05, a significant difference when compared with the 




Fig. 6. The histopathological changes in the liver in BDL-induced cholestasis stained with H&E and Masson’s trichrome stain (×40). After 
BDL operation, the rats in PG-treated groups were orally given PG at 0, 10 and 50 mg/kg body weight/day for 4 weeks. The sham-operated 
groups were orally given with the same volume of saline as the BDL-treated animals that received PG. The livers of the sham-operated rats 
had normal histological features of liver, but the livers collected from BDL-operated rats showed typical histological changes, which were 
characterized by bridge fibrosis formation in the portal area prominent ductular proliferation (thin arrows), mild-to-moderate PNL and 
lymphocyte infiltration (thin arrows) and piecemeal necrosis (thick arrows) in the periportal region. Asterisk indicates bridge fibrosis by 
ductular proliferation and collagen accumulation in portal area. BDL: bile duct ligation; H&E: hematoxylin and eosin; PNL: 
polymorphonuclear leukocyte.
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Serum TGF- β level 
The plasma fibrogenic cytokines, TGF-β, which play important roles in 
the activation of hepatic stellate cells, were significantly increased by 2.2-
fold in the group treated with BDL alone (Fig. 7). However, TGF- β1 
production was significantly reduced in PG-treated BDL rats than in the rats 
treated with BDL alone. 
 
 
Fig. 7. Serum level of TGF-b1 in the BDL-induced cholestasis. After BDL operation, the 
rats in PG-treated groups were orally given PG at 0, 10 and 50 mg/kg body weight/day for 4 
weeks. The sham-operated groups were orally given the same volume of saline as the BDL-
treated animals that received PG. Values are expressed as means ± SEM. ap < 0.05, a 
significant difference when compared with the sham-operated group. bp < 0.05, a significant 
difference when compared with the group treated with BDL alone. TGF-β1: transforming 
growth factor-beta 1; BDL: bile duct ligation. 
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Discussion 
One of the standard animal models for research on cholestasis is the total 
ligation of the common BDL model (Georgiev et al., 2008). During bile duct 
obstruction and the subsequent cholestasis, increased concentrations of bile 
acids and toxins in the liver result in the activation of Kupffer and hepatic 
stellate cells (Gaillard et al., 1991). In the early stage of BDL, even 8 h after 
BDL, the liver presented clusters of injured hepatocytes and initiation of 
cholangiocellular proliferation in the large bile duct (Georgiev et al., 2008; 
Portincasa et al., 2007). In the present study, levels of serum liver enzymes 
in the short-term BDL alone group were significantly increased by BDL in 
comparison with the sham-operated group, and these elevated enzyme levels 
were decreased by pretreatment of PG. Serum levels of ALT, AST and TBIL 
are classical markers of obstructive cholestasis in the clinical setting. 
Clinically, the AST to ALT ratio is significantly elevated in patients with 
advanced fibrosis (Su et al., 2009). In long-term BDL study, elevated serum 
levels of ALT, AST and TBIL, together with the AST/ALT ratio were 
observed in rats treated with long-term BDL alone, but these elevations were 
ameliorated in the PG-treated BDL groups.  
BDL induces a type of liver fibrosis that etiologically and pathogenically 
resembles the biliary fibrosis in human (Serviddio et al., 2004). The bile 
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stasis and backpressure that occur because of the obstruction induce 
proliferation of the duct epithelial cells and looping and reduplication of the 
ducts, which is termed ‘‘bile duct proliferation’’. The hepatocellular 
degeneration and death observed in cholestasis have been reported to be 
related to the retention of toxic bile salts, which leads to oxidative stress via 
the entry of nicotinamide adenine dinucleotide phosphate oxidase isoforms 
into the immune activation pathway (Trauner et al., 1998). It has been 
suggested that hepatocyte apoptosis and/or necrosis may be associated with 
the activation of Kupffer cells, which release TGF-β and tumor necrosis 
factor-a (Friedman, 2000; Gressner et al., 2002; Lee et al., 1995). 
Furthermore, TGF-β is upregulated in liver fibrosis and known to cause 
hepatic satellite cell proliferation and the production of collagen (Gressner et 
al., 2002). Increased TGF-β expression has been reported in bile duct-
obstructed liver tissue and it leads to the pathological accumulation of 
extracellular matrix protein (Canbakan et al., 2009; Reyes-Gordillo K et al., 
2008). Intracellular oxidative stress is a major contributor to fibrogenesis, 
and recent studies have shown the induction of profibrogenic TGF-β1 by 
peroxide radicals, thereby providing a rationale for the use of intracellular 
antioxidants as adjunctive antifibrotic agents (Breitkopf et al., 2005; Teixeira 
et al., 2007). Several promising drugs derived from plants may be useful in 
antifibrotic combination therapy. Silibinin from milk thistle (Silybum 
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marianum) was shown to reduce hepatic collagen accumulation in rat biliary 
fibrosis secondary to bile duct occlusion and baicalein from Sho-saiko-to 
also showed antifibrotic properties in activated hepatic satellite cell in vitro 
(Chen et al., 2005; Jia et al., 2001; Shimizu et al., 1999).  
PG ameliorated hepatotoxic chemical-induced hepatic injury, which 
inhibited the production of excessive ROS and strongly inhibited HCV 
genotype 1b replicon replication in Huh7 cells (Lim et al., 2011; Kim et al., 
2011). In addition, triterpenoid saponins from Platycodon grandiflorum 
significantly prevented the elevation of hepatic alpha1 (I) procollagen 
messenger RNA and alpha-smooth muscle actin expressions via HSC 
inactivation in CCl4-intoxicated rats. 
Recent findings suggest that the Wnt/b-catenin pathway is strongly 
involved in the normal activation and proliferation of adult hepatic 
progenitor cells in both acute and chronic human liver diseases (Spee et al., 
2010). Canonical Wnt/b-catenin signaling also suppresses the expression and 
promoter activation of peroxisome proliferator-activated receptor γ (PPARγ) 
in HSC transdifferentiation. Moreover, PPARγ agonists inhibit HSC 
activation and counteract liver fibrosis in models of cholestasis (Fiorucci et 
al., 2005; Galli et al., 2002; Yang et al., 2006). In addition, some studies 
have shown that PPARγ agonist, such as rosiglitazone, improves steatosis 
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and transaminase levels, which is an effect related to an improvement in 
insulin sensitivity (Galli et al., 2002). It was recently reported that 
Platycodon grandiflorum extract and its triterpenoid saponins enhanced 
hepatic and adipocyte insulin sensitivity, possibly by activating the PPARγ 
(Galli et al., 2002; Kim et al., 2009; Kwon et al., 2009 and 2012). Kwon et 
al. (2012) reported that triterpenoid saponins including platycoside E, 
platycodin D2, platycodin D3, platyconic acid and platycodin D may be 
potential PPARγ activators and possible agonists and reduce triglyceride 
accumulation in the liver by enhancing hepatic insulin sensitivity (Kwon et 
al., 2012). In addition, Platycodon grandiflorum extracts improved 
nonalcoholic steatohepatitis mediating the anti-steatohepatitis action of the 
PPARγ (Kim et al., 2009; Noh et al., 2010). In accordance with the previous 
data, PG in the present study inhibited lipid peroxidation and reduced BDL-
induced hepatic GSH depletion as well as restored hepatic Cu/Zn SOD 
activities in the liver. The level of TGF-β1 was significantly increased in the 
group treated with BDL alone, whereas it was significantly ameliorated in 
the BDL group treated with PG. Consistently, many histopathological 
features of cholestasis such as extensive bile duct proliferation, the formation 
of periportal fibrosis, focal necrosis, confluent necrosis, piecemeal necrosis, 
focal and portal inflammation, bile duct proliferation and fibrosis were 
observed in the group treated with BDL alone. These histopathological 
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features associated with cholestasis were attenuated by PG, although PG did 
not significantly decrease the number of bile ducts among the BDL groups. 
In conclusion, the protective effect of PG against BDL-induced hepatic 
fibrosis may be mainly associated with the ability of this extract to attenuate 
oxidative stress and to inhibit TGF-β1. The capacity of PG to attenuate 
oxidative stress and suppress the release of TGF-β1, and the advantage of it 
being a nontoxic natural product are important factors that make this extract 
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Chapter 3. Platycodin D attenuates bile duct ligation-induced hepatic 
injury and fibrosis in mice 
 
Abstract 
Platycodin D (PD) is the major triterpene saponin in the root of 
Platycodon grandiflorum. The aim of the present study was to evaluate the 
protective effects of PD on bile duct ligation (BDL)-induced cholestasis in 
mice. Mice were allocated to five groups: sham, BDL alone, and BDL with 
PD treatment at 1, 2, and 4 mg/kg. PD was administered to the mice for 28 
consecutive days after the BDL operation. PD treatment of BDL-operated 
mice decreased serum alanine aminotransferase, serum aspartate 
aminotransferase, and total bilirubin levels by up to 37%, 31%, and 41%, 
respectively, in comparison with the levels in mice that underwent BDL 
alone. PD treatment attenuated oxidative stress, as evidenced by an increase 
in antioxidative enzyme levels glutathione and superoxide dismutase 
together with a decrease in lipid peroxidation and oxidative stress indices 
levels of malondialdehyde and nitric oxide. Histopathological studies further 
confirmed the protective effects of PD on cholestasis-induced hepatic injury 
and liver fibrosis in mice. In addition, nuclear factor-kappa B and inducible 
nitric oxide synthase levels significantly decreased after PD treatment, as did 
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the levels of hepatocyte apoptosis. Taken together, these results suggest that 
PD treatment might be beneficial in cholestasis-induced hepatotoxicity. 
 
Introduction 
Cholestasis can be defined as bile flow impairment resulting from the 
obstruction of the bile duct or a functional defect in bile formation (Arrese 
and Trauner, 2003; Clavien et al., 2007). In the early stages of cholestasis, 
toxic bile salts damage hepatocytes due to their surfactant properties and the 
damaged hepatocytes generate reactive oxygen species (ROS) (Copple et al., 
2010). ROS not only amplify inflammation, but also stimulate hepatic 
stellate cells to promote fibrosis by lipid peroxidation. Therefore, reduction 
of oxidative stress can play an essential role in the treatment of obstructive 
cholestasis. Demirbilek et al. (2007) reported that, 3-hydroxy-
3methylglutarly coenzyme A (HMG-Co-A) reductase inhibitor, a statin that 
is present in cholesterol-lowering drugs and has an antioxidant effect, can be 
useful in cholestasis patients (Demirbilek et al., 2007). 
Triterpenoid saponins from Platycodon grandiflorum have been shown to 
exhibit a variety of pharmacological activities (Khanal et al., 2009; Kim et 
al., 2001; Lee et al., 2008; Xie et al., 2009; Yu and Kim, 2010). Among these 
77 
terpenoid saponins, platycodin D (PD) is the most potent in terms of its 
effect on peroxyl radical-scavenging activity and various other 
pharmacological effects (Kim et al., 2001; Ryu et al., 2012). In addition, PD 
has been reported to inhibit HMG-Co-A reductase, a key enzyme that 
catalyzes the ratelimiting step in the cholesterol biosynthetic pathway (Wu et 
al., 2011). 
The present study investigated the hepatoprotective effect of PD on 
chronic cholestasis-induced hepatic injury and fibrosis in bile duct ligation 
(BDL)-operated mice. 
 
Materials and methods 
Chemicals and reagents 
PD (approximately 98% purity) from Platycodon grandiflorum roots was 
purchased from Innoten (Seoul, Korea). The assay kits for superoxide 
dismutase (SOD), thiobarbituric acid reactive substances (TBARS), and 
glutathione (GSH) were obtained from Cayman (Ann Arbor, MI, USA). The 
assay kit for nitric oxide (NO) was purchased from BioAssay Systems 
(Hayward, CA, USA). Serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and total bilirubin (TBIL) test kits were obtained 
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from IDEXX (Westbrook, ME, USA). The terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) 
staining and immunostaining kits were purchased from Millipore (Billerica, 
MA, USA) and Vector Laboratories (Burlingame, CA, USA), respectively. 
The anti-nuclear factor-kappa B (NF-κB) p65 and anti-inducible nitric oxide 
synthase (iNOS) antibodies were purchased from Abcam (Cambridge, UK). 
All other reagents were from Sigma Chemicals (St. Louis, MO, USA).  
 
Animals and treatments 
Male Crl:CD-1 (ICR) mice (6-7 week) were obtained from Orient Bio 
(Seongnam, Korea) and acclimated for 1 week before the experiments. The 
mice were housed under a 12 h light/dark cycle (22-23°C) and provided with 
standard mice food pellets and water ad libitum. The mice were randomly 
allocated into 5 groups as follows: group 1 (sham, n = 5), group 2 (BDL 
alone, n = 5), group 3 (BDL and 1 mg/kg of PD, n = 5), group 4 (BDL and 2 
mg/kg of PD, n = 5), and group 5 (BDL and 4 mg/kg of PD, n = 5). BDL was 
performed under anesthesia with an intraperitoneal injection of a 
combination of zolazepam and tiletamine (Zoletil 50; Virbac, Carros, France). 
After midline laparotomy the duodenum was retracted, and the common bile 
duct was carefully double-ligated with a 6-0 nylon suture and dissected. 
79 
Sham group mice received an identical laparotomy and isolation of the 
common bile duct without ligation. After the BDL operation, the sham and 
BDL alone groups were orally administered distilled water and the other 
groups were orally administered PD (1, 2, and 4 mg/kg) for 28 consecutive 
days. PD was dissolved in distilled water and the dosing volume was 5 
mL/kg body weight. Twenty eight days after the BDL operation, the mice 
were sacrificed by cardiac puncture under anesthesia with carbon dioxide. 
Blood was collected and the serum was separated by centrifugation at 800 g 
for 15 min for the biochemical investigations. Liver samples were taken from 
each mouse for the histopathological and biochemical examinations. The left 
lobes of the liver were fixed immediately with a 10% buffered formalin 
phosphate solution. The serum samples and the other parts of the liver were 
stored at -70°C until analysis. The experimental protocols were approved by 
the Institutional Animal Care and Use Committee of Chungnam National 
University (Daejeon, Korea). 
 
Serum biochemical examination 
The serum ALT, AST and TBIL activities were determined on a dry 
chemistry system: the VetTest 8008 blood chemistry analyzer (IDEXX). 
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Determination of hepatic GSH, SOD, TBARS, and NO levels 
The hepatic GSH level was determined using the improved DTNB [5,50-
dithiobis-(2-nitrobenzoic acid)] method. The SOD level was measured using 
the tetrazolium salt assay. The levels of malondialdehyde (MDA), the 
terminal product of lipid peroxidation, were measured with the thiobarbituric 
acid reduction method using a commercially available kit. NO levels were 
measured by the improved Griess method. All assays were performed 
according to the manufacturer’s protocols. 
 
Histopathological examination 
Liver slices were taken from a part of the left lobe in each group, fixed in 
a 10% buffered formalin phosphate solution, and embedded in paraffin. The 
block was cut into 5 µm sections and stained with hematoxylin and eosin 
(H&E) and Masson’s trichrome stain. The typical histopathological 
alterations such as portal inflammation, focal necrosis, piecemeal necrosis, 
ductular proliferation, edema and fibrosis were evaluated with H&E stained 
liver section. The degree of fibrosis were evaluated and graded with 
Masson’s trichrome stained liver sections according to the modified Ishak 
system as follows: 0, no fibrosis; 1, fibrous expansion of some portal tracts, 
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with or without short fibrous septa; 2, fibrous expansion of most portal tracts, 
with or without short fibrous septa; 3, fibrous expansion of portal tracts with 
occasional portal to portal bridging; 4, fibrous expansion of portal tracts with 
marked portal to portal bridging as well as portal to central; 5, marked 
bridging portal to portal and/or portal to central with occasional nodules; 6, 
cirrhosis, probable or definite (Ishak et al., 1995; Knodell et al., 1981). 
 
Immunohistochemical analysis 
Apoptotic nuclei were detected with the TUNEL method using an 
apoptosis detection kit (ApopTag Peroxidase In Situ Apoptosis Detection Kit; 
Millipore). Immunostaining for NF-κB p65 and iNOS was performed with 
anti-NF-κB p65 and anti-iNOS antibodies (Abcam, Cambridge, UK) using 
the Vectastain Elite ABC Rabbit IgG Kit (Vector Laboratories) according to 
the manufacturer’s protocol. The color development steps were carried out 
using 3,30-diaminobenzidine (DAB) as a chromogen which produces a dark 
brown color in positive staining. The immunostaining for NF-κB was scored 
according to its intensity: 0, no specific staining (no cytoplasmic and nuclear 
staining); 1, weakly positive (mild cytoplasmic staining and no nuclear 
staining); 2, moderately positive (moderate cytoplasmic staining and present 
or absent nuclear staining); and 3, strongly positive (severe cytoplasmic and 
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nuclear staining) (Demirbilek et al., 2007). Image analysis for the 
quantification of TUNEL-positive stained cell number and relative intensity 
of iNOS staining was performed using Image J (National Institutes of Health, 




The results were expressed as the mean ± standard error (SEM). 
Significant differences among the experimental groups were determined 
using the one-way analysis of variance (ANOVA) test or the non-parametric 
Kruskal-Wallis test. Where significant effects were found, post-hoc analyses 
using the Tukey’s test or Mann-Whitney U-test were test was performed and 
p<0.05 was considered statistically significant. 
 
Results 
Serum hepatic enzyme activity 
Serum ALT and AST levels significantly increased to 271.4 ± 16.88 and 
307 ± 10.29 U/L in mice that received BDL alone group animals (p < 0.05; 
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Table 1). PD administration reduced the cholestasis-induced increase in ALT 
and AST levels in a dosedependent manner. Similarly, BDL alone mice also 
showed a significant elevation in their TBIL concentration in comparison 
with the levels in the sham-treated group (p<0.05; Table 1). The levels of 
TBIL in the PD-treated groups (1, 2, and 4 mg/kg) were markedly lower than 
those in the group that received BDL alone (26%, 31%, and 41% 
respectively; p < 0.05; Table 1). 
 
Table 1. Effect of PD on serum enzyme in the BDL-induced liver injury (n = 
5/group). Mice were given orally PD (0, 1, 2 and 4 mg/kg) once daily for 28 
consecutive days after BDL. 
Group ALT AST TBIL 
Sham 12.25 ± 0.85 b** 13.33 ± 1.66 b** 4.27 ± 2.56 b** 
BDL-alone 271.40 ± 16.88 a** 307.60 ± 10.29 a** 243.44 ± 10.46 a** 
PD 1 mg/kg 248.40 ± 32.07 a** 241.33 ± 15.94 a** 179.02 ± 9.38 a**, b* 
PD 2 mg/kg 193.75 ± 28.25 a** 232.20 ± 45.53 a** 167.04 ± 8.62 a**, b* 
PD 4 mg/kg 170.60 ± 29.73 a**, b* 210.20 ± 11.29 a**, b* 141.62 ± 14.01 a**, b** 
Values are expressed as means ± SEM. ‘‘a’’ denotes statistically significant difference in 
comparison with the sham group and ‘‘b’’ denotes statistically significant difference in 
comparison with the BDL-alone group (*p < 0.05; **p < 0.01; one-way ANOVA followed by 
Tukey’s post hoc test). 
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Evaluation of hepatic GSH, SOD, TBARS, and NO levels 
The obstruction of the bile duct in the group that received BDL alone 
caused a significant decrease in the levels of antioxidant enzymes (GSH and 
SOD), but treatment with PD partially restored these levels (p<0.05). The 
indices of oxidative stress (the levels of NO and TBARS) increased by 
approximately 93% and 121% in the group that received BDL alone 
compared with the levels in the sham-treated group, while the PD-treated 
group showed markedly reduced levels of these enzymes compared with the 
levels in the group that received BDL alone (up to 34% and 27% reductions, 




Fig. 1. Effect of PD on GSH, SOD, TBARS and NO in the BDL-induced liver injury (n = 
5/group). Mice were given orally PD (0, 1, 2 and 4 mg/kg) once daily for 28 consecutive 
days after BDL. Values are expressed as means ± SEM. ‘‘a’’ denotes statistically significant 
difference in comparison with the sham group and ‘‘b’’ denotes statistically significant 
difference in comparison with the BDL-alone group (*p < 0.05; **p < 0.01; one-way 




The liver tissue architecture in the sham-operated mice remained intact 
with no morphological alterations, while hepatocyte necrosis, polymorphic 
nuclei and broad ductular proliferation were observed in the mice that 
received BDL alone (Fig. 2). Massive bridging fibrosis around the portal and 
central vein was also observed in the mice that received BDL alone (Fig. 3). 
The low dose of PD (1 mg/kg) did not prevent this histological alteration, 
with bridging fibrosis observed in the portal area and ballooning 
degeneration of the hepatocyte also present (Fig. 3). The mice that were 
treated with 4 mg/kg PD, however, had markedly decreased ductular 




Fig. 2. Effect of PD on histopathological alteration in the BDL-induced liver injury (n = 
5/group). The histopathological changes of the liver stained with hematoxylin and eosin 
(×200). Mice were given orally PD (0, 1, 2 and 4 mg/kg) once daily for 28 consecutive days 
after BDL. (A) Sham group; (B) BDL-alone group; (C) PD (1 mg/kg) treated group; (D) PD 
(2 mg/kg) treated group; (E) PD (4 mg/kg) treated group. In the sham group, livers show 
normal morphology with intact cytoplasm. In the BDL-alone group, livers show massive 
ductular proliferation around portal area and feathery degeneration of hepatocyte. These 
alterations were markedly decreased in the PD (4 mg/kg) treated group. Arrows indicate 







Fig. 3. Effect of PD on fibrosis in the BDL-induced liver injury (n = 5/group). The fibrosis 
of the liver stained with Masson’s trichrome (×100). Mice were given orally PD (0, 1, 2 and 
4 mg/kg) once daily for 28 consecutive days after BDL. (A) Sham group; (B) BDL-alone 
group; (C) PD (1 mg/kg) treated group; (D) PD (2 mg/kg) treated group; (E) PD (4 mg/kg) 
treated group. Broad fibrosis and fibrous bridge were present in the BDL-alone group 
(Grade 4-5). Fibrosis areas were markedly decreased in the PD treated group (Grade 1-2). 
‘‘a’’ denotes statistically significant difference in comparison with the sham group and ‘‘b’’ 
denotes statistically significant difference in comparison with the BDLalone group (*p < 




Evaluation of NF-κB immunoreactivity showed that the degree of 
hepatocyte NF-κB activation in the group that received BDL alone was 
significantly higher than that in the sham-operated group (p<0.05; Fig 4). 
NF-κB activation appeared scattered at the parenchyma, predominantly 
adjacent to the inflamed portal tracts. The expression of iNOS was also 
increased in the group that received BDL alone compared with that in the 
sham-treated group (Fig. 4). However, the expression levels of NF-κB p65 
and iNOS were markedly attenuated by PD treatment (p<0.05). In 
histological evaluation of apoptosis, the number of TUNEL-positive cells 
increased significantly in the ductal proliferation areas of the group that 
received BDL alone, whereas it was decreased by 18%, 40%, and 49% in the 





Fig. 4. Effect of PD on NF-κB (×200) and iNOS (×100) expression in the BDL-induced liver 
injury (n = 5/group). Mice were given orally PD (0, 1, 2 and 4 mg/kg) once daily for 28 
consecutive days after BDL. (A) Sham group; (B) BDL-alone group; (C) PD (1 mg/kg) 
treated group; (D) PD (2 mg/kg) treated group; (E) PD (4 mg/kg) treated group. Staining 
score for NF-jB and relative intensity for iNOS are expressed as means ± SEM. ‘‘a’’ denotes 
statistically significant difference in comparison with the sham group and ‘‘b’’ denotes 
statistically significant difference in comparison with the BDL-alone group (*p < 0.05; **p < 





Fig. 5. The effects of PD on apoptotic cells in the BDL-induced liver injury (n = 5/group). 
The apoptotic cells were showed in TUNEL stained livers (×200). Mice were given orally 
PD (0, 1, 2 and 4 mg/kg) once daily for 28 consecutive days after BDL. (A) Sham group; (B) 
BDL-alone group; (C) PD (1 mg/kg) treated group; (D) PD (2 mg/kg) treated group; (E) PD 
(4 mg/kg) treated group. Arrows indicate apoptotic cells. The presence of TUNEL-positive 
cells were measured by the image analyzer. Values are expressed as means ± SEM. adenotes 
statistically significant difference in comparison with the sham group and bdenotes 
statistically significant difference in comparison with the BDL alone group (*p < 0.05; **p < 







Several studies have revealed terpenoid saponins from the root of 
Platycodon grandiflorum to have a protective effect against chemically 
induced hepatotoxicity (Khanal et al., 2009; Lee et al., 2001; Lim et al., 
2011). Based on these findings, the present study aimed to examine the 
protective effect of PD, which has the most potent biological activity of all 
the terpenoid saponins from Platycodon grandiflorum against chronic 
cholestasis-induced hepatotoxicity.  
In the present study, we used the mice BDL model to assess the protective 
effect of PD against cholestasis. Bile duct ligation is a good model to 
evaluate for the protective or curative effect of certain compounds against 
cholestasis-induced liver injury. Furthermore, mice develop bile duct and 
septal proliferations with leukocyte infiltration and liver fibrosis similar to 
human. In addition, the presence of gallbladder in mice helps to confirm the 
proper ligation as against rats with no gallbladder (Aller et al., 2008; 
Georgiev et al., 2008; Heinrich et al., 2010). Georgiev et al. (2008) reported 
that during 42 days of BDL, only nine out of 63 mice became moribund. In 
the present study, there was no mortality during 28 days of experiments. 
During the experiment period, all BDL-operated mice showed clinical 
symptoms of jaundice by BDL-induced cholestasis such as a yellowish 
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pigmentation of skin and mucous membrane, and dark urine. In necropsy, all 
the operated mice had markedly dilated gallbladder, which means the 
confirmation of the BDL operation. 
During cholestasis, accumulated bile salts cause damage to the 
hepatocytes and elevate serum ALT and AST levels. In addition, the 
increased TBIL that is observed in cholestasis reflects the obstruction-
induced deficiency of the bile duct at excreting bilirubin. In the present study, 
the serum ALT, AST, and TBIL levels in the group that received BDL alone 
significantly increased after BDL, which indicated that the common bile duct 
was completely ligated. These elevated serum enzymes levels markedly 
decreased by PD treatment in a dose-dependent manner. Obstruction of the 
bile duct causes the generation of massive oxidative stress and the depletion 
of antioxidant enzymes during cholestasis. Pastor et al. (1997) reported that 
prooxidant/antioxidant balances shifted towards lipid peroxidation under the 
conditions of BDL (Pastor et al., 1997). In the group that received BDL 
alone, the cholestasis-induced depletion of antioxidant enzymes such as GSH 
and SOD was markedly increased in contrast with the effect on the lipid 
peroxidation indices TBARS and NO. In this study, treatment of BDL-
operated mice with PD inhibited lipid peroxidation and reduced 
cholestasisinduced hepatic GSH depletion, and also restored hepatic SOD 
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activities in the liver. 
Under normal condition, NO has several beneficial effects, such as anti-
microbial, anti-viral, and anti-tumor activities (Bogdan, 2001). However, 
excessive NO production due to the overexpression of iNOS can be 
detrimental to normal tissue, both directly and indirectly through its 
interaction with ROS, which forms the cytotoxic oxidizing agent 
peroxynitrite (Davis et al., 2001). The expression of iNOS is regulated by 
NF-κB activation, which may result in a sustained high level of NO (Xie et 
al., 1994). Lin et al. reported an anti-fibrotic effect of a herbal extract 
alongside reduced expression of NF-κB and iNOS (Lin et al., 2008). In 
addition, Ahn et al. (2005) reported that PD downregulated iNOS and COX 
II via suppression of NF-κB in RAW 264.7 cells (Ahn et al., 2005). In the 
present study, the group that received BDL alone showed activation of NF-
κB accompanied by increased iNOS levels. The PD-treated group exhibited 
ameliorated NF-κB and iNOS expression. Consistent with the results for 
iNOS and NF-κB expression, the decrease in hepatic NO levels as a result of 
PD treatment probably resulted from the inhibited NF-κB expression via the 
suppression of iNOS. 
Cholestasis-induced apoptosis of liver cells was detected using TUNEL 
staining. In the present study, hepatocyte apoptosis was related to oxidative 
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stress status; the group that received BDL alone treatment showed an 
increase in the number apoptotic cells accompanied by elevated levels of 
ROS, whereas PD treatment ameliorated both ROS and the hepatic apoptosis. 
Even though several factors may be involved in hepatocyte apoptosis during 
cholestasis, the generation of ROS plays a key role in the apoptosis of liver 
cells by altering the liver’s redox status (Maillette de Buy Wenniger and 
Beuers, 2010). Therefore, the reduction in the number of apoptotic cells in 
the PD-treated group may have resulted from an improvement of the redox 
status in cholestasis-induced hepatic injury. 
Obstruction of the biliary system induces retention of bile. Chronic bile 
retention causes bile duct dilatation and proliferation, activate hepatic stellate 
cells to produce collagen, and eventually leads to periportal and 
perineoductular fibrosis (Copple et al., 2010), which were confirmed by 
trichrome staining in the present study. The liver tissue from mice that 
received BDL alone showed broad ductal proliferation and the formation of a 
fibrous connective tissue bridge between the portal tracts. Treatment with PD 
significantly reduced the proliferation of the bile duct and fibrosis. These 
results were consistent with the results of a previous study on statins, a class 
of hypolipidemic drugs, in the BDL model. According to previous study, bile 
acids were formed as a result of hydroxylation of endogenous cholesterol; 
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thus lowering cholesterol levels can promote the downregulation of 
enterohepatic bile acid circulation (Staels and Fonseca, 2009). It was 
reported that statins might improve hypercholesterolemia and bile acid 
accumulation in primary biliary cirrhosis patients by down-regulating HMG-
CoA reductase, the enzyme that is responsible for the production of 
cholesterol (Demirbilek et al., 2007; Kolouchova et al., 2011). PD has been 
shown to effectively lower cholesterol levels in hypercholesterolemic mice 
with HMG-CoA inhibitor activity (Wu et al., 2011; Zhao et al., 2006). 
Furthermore, Zhao et al. (2006) reported that PD showed a human acyl-
coenzyme A: cholesterol acyltransferase inhibitory activity, which was 
attributable to the lowering of hepatic cholesterol storage (Zhao et al., 2006). 
Therefore, the cholesterol-decreasing activity of PD likely partially 
contributed to the ameliorated TBIL level in the serum and the decreased 
ductular proliferation in the present study.  
Taken together, these results indicate that treatment with PD reduced 
oxidative stress and ameliorated apoptosis and tissue fibrosis in a cholestasis-
induced hepatotoxic liver. Although further studies should be performed 
prior to the clinical use of PD, these results suggest that PD treatment might 
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Chapter 4. Platycodin D-induced apoptosis acin CT26 cells and its 
synergistic effect with cisplatin on tumor bearing mice 
 
Abstract 
There has been growing interest in natural anti-cancer compounds due to 
their relative safety. Platycodin D (PD) is a triterpenoid saponin with various 
pharmacological activities. We aimed to assess anti-cancer effect of PD and 
its synergistic effect with cisplatin against CT26 cells using in vitro and in 
vivo study. In vitro study, the IC50 of PD and cisplatin in CT26 cells were 8.2 
and 1.2 μM, respectively, and the combination of both compounds showed a 
synergistic effect (CI<1). In addition, PD treatment induced apoptosis in 
CT26 cells in a dose- and time-dependent manner with increased 
phosphorylation of extracellular-signal-regulated kinase and c-Jun N-
terminal kinase. In vivo study, CT26 cells were injected into the right frank 
of the mice and the mice were treated for 4 weeks with single PD and 
cisplatin and their combination. The combination treatment showed a 
synergistic effect on tumor growth inhibition and decreased cisplatin-induced 
oxidative stress in the liver and kidney tissue. Taken together, PD can be a 
candidate for combination therapy with chemotherapeutic agents after 
careful safety assessment study. 
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Introduction 
Anticancer drugs exert their therapeutic effect by killing rapidly dividing 
tumor cells. However, the tumor cells have multiple survival pathways to 
resist chemotherapeutic agents. Cisplatin (cis-diamminedichloroplatinum II) 
is one of the most potent platinum-containing anticancer drug used for many 
types of cancer, including testicular, ovarian and cervical carcinoma (Pabla 
and Dong, 2008). Despite its effective chemotherapeutic properties, dose-
related side effects limit its clinical application, such as nausea and vomiting, 
ototoxicity and nephrotoxicity (Arany and Safirstein, 2003; Pabla and Dong, 
2008). Although the nephrotoxicity is regarded as the most frequent and 
severe side effect, high dose cisplatin was reported to induce additional 
hepatotoxicity (Iraz et al., 2006; İşeri et al., 2007). Oxidative stress, 
inflammation and apoptosis are main factors for the cisplatin-induced 
damage (Yao et al., 2007).  
A number of studies so far reported that co-administration of dietary or 
pharmaceutical antioxidants with chemotherapeutic agents decreased 
anticancer treatment-related side-effects (Pace et al., 2003; Sieja, 2000). 
Moreover, drug combinations are assumed to enhance therapeutic efficacy 
compared to single drugs (Chiu et al., 2009; Koppikar et al., 2010; Sandler et 
al., 2006; Webb et al., 2007). 
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The root of Platycodon grandiflorum has been traditionally used as a 
medicine for various respiratory diseases, including bronchitis, asthma and 
pulmonary tuberculosis in East Asian countries (Takagi and Lee, 1972). The 
triterpenoid saponins from Platycodon grandiflorum exhibited a variety of 
pharmacological activities, such as anti-inflammatory, anti-cancer and 
immune enhancing effects (Kim et al., 2008a; Shin et al., 2009; Xie et al., 
2009). In our previous study, platycodin D (PD) ameliorated cisplatin-
induced nephrotoxicity in mice with dose-dependent manners (Kim et al., 
2012). Furthermore, the PD from Platycodon grandiflorum was reported to 
exhibit growth inhibition properties in several types of cancer cells (Chun et 
al., 2013; Kim et al., 2008a; Yu and Kim, 2010). To our knowledge, there 
has been no report on the anticancer activity of PD and its combined effect 
with cisplatin against CT26 cells. The aim of the present study was to 
evaluate the efficacy of the PD as an anticancer agent and its combined effect 
with cisplatin using in vitro and in vivo as well. We also assessed antioxidant 
properties of PD in long-term cisplatin treated tumor bearing mice. 
  
Materials and methods 
Chemicals and reagents 
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PD (approximately 98% purity) was purchased from Innoten (Seoul, 
Korea). Assay kits for glutathione (GSH), superoxide dismutase (SOD) and 
thiobarbituric acid (TBARS) were obtained from Cayman (Ann Arbor, MI, 
USA). The Nitric oxide (NO) kit was from BioAssay Systems (Hayward, CA, 
USA). Serum alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), creatinine (CRE) and blood urea nitrogen (BUN) test kits were 
obtained from IDEXX (Westbrook, ME, USA). Extracellular-signal-
regulated kinase (ERK), p-ERK, c-Jun N-terminal kinase (JNK) and p-JNK 
antibody was purchased from Cell Signalling Technology (Danvers, MA, 
USA). All other reagents were from Sigma Chemicals (St. Louis, MO, USA). 
 
In vitro study 
Determination of combination index 
The viability of CT26 cell was examined using resazurin assay. CT26 cells 
(Colon carcinoma; KCBL. 80009; Korean Cell Line Bank; 5 x 103 cells/well) 
were plated for 24 h into 96-well tissue culture plates with DMEM 
containing 10% v/v fetal bovine serum (FBS) and 1% penicillin-
streptomycin. The cell viability assay was performed with serial 
concentration of cisplatin (0, 0.3, 0.6, 1.2, 2.5, 5.0, 10.0 and 20.0 μM), PD (0, 
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3.0, 3.3, 5.5, 6.0, 6.5, 11.0, 12.0, 13.0, 22.0, 24.0 and 26.0 μM). After 24, 48 
and 72 h of incubation, 10 μL resazurin solution was added into medium and 
incubated cells for 3 h at 37°C. Absorbance was measured at 570 nm and 600 
nm using a micro-titer plate reader.  
For synergism assay, serial concentration of the drug, either as a single 
agent or in combination of both cisplatin and PD were added to the wells. 
After 48 h of incubation, the viability of cell was assessed using resazurin 
assay. The type of drug interaction was assessed by the combination index 
(CI) according to the method of Chou and Talalay (1984). Interactions 
between cisplatin and PD were assessed using isobologram analyses 
(CalcuSyn Software, Biosoft, Ferguson, MO, USA). A combined index (CI) 
<1 was regard as synergism, CI=1 indicating additive interactions, and CI>1 
representing antagonism. All assays were performed in triplicates. 
 
Cell cycle analysis 
Cell cycle distribution was monitored by flow-cytometry. Cells were 
seeded at the density of 1 × 105 per well in 6-well plates. After 24 h, cells 
were treated with 20 μM of PD for 24, 48 and 72 h. Control and treated cells 
were harvested, washed twice with PBS, and fixed in 70% ethanol overnight 
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at -20°C. Fixed cells were washed twice with PBS, incubated with 1 mL of 
propidium iodide (PI) solution (0.1% Triton X-100, 10 μg/mL PI, and 100 
μg/mL DNase-free RNase A in PBS) for 30 min at 37°C. Stained cells were 
analysed using a FACS Canto II and Cell Quest software (Becton Dickinson). 
 
Apoptosis assay 
Apoptosis was determined using Annexin V-FITC/ PI double staining. 
Cells were seeded at the density of 1 × 106 per well in 6-well plates. After 24 
h, cells were treated with 0, 10, 20 and 40 μM of PD for 48 h. After 
incubation, cells were washed cells twice with PBS. Cells were resuspended 
in 1×binding buffer at a concentration of 1 × 106 cells/mL and 100 μL of 
suspended cells were incubated in the dark at room temperature with 5 µL of 
FITC Annexin V and 5 µL of PI. After 20 min of incubation, 400 µL of 
1×binding buffer was added to each tube. The samples were analysed within 
1 h. Data were analysed by flow-cytometry using the FACS Canto II and 





Western blot analysis 
Cells were seeded at the density of 1 × 105 per well in 6-well plates. After 
24 h, cells were treated with 0, 20 and 40 μM of PD for 24, 48 and 72 h. 
After incubation, the cells were lysed with lysis buffer (20 mM Tris-HCl pH 
8, 150 mM NaCl) containing a protease inhibitor cocktail. After protein 
quantification, 20 µg of protein were separated using a 12% SDS-PAGE. The 
proteins were transferred onto a nitrocellulose membrane in a Semi-Dry 
Transfer system from Hoefer (Holliston, MA, USA). The membrane was 
blocked with 5% (w/v) dry milk in 1X TBS with 20% TWEEN-20 (TBS-T) 
and incubated with aliquot volume of anti-primary antibody. Horseradish 
peroxidase-conjugated anti-rabbit and mouse IgG (1:5000) was used. 
Immunoreactivity was visualized using an enhanced chemiluminescence 
detection (ECL) kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). 
 
In vivo study 
Animals and treatments 
Balb/c mice (5-6 week; 32-36 g) were obtained from Orient Bio 
(Seongnam, Korea) and housed with standard chow (Charles River Inc., 
Richmond, IN, USA) and water ad libitum under the standard room 
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temperature (25°C) and 12 h light/dark cycle. After one week of acclimation, 
CT26 cells (2 x 105) were injected into the right frank of all healthy mice 
except for normal group. To explore the therapeutic efficacy of cisplatin and 
PD, the mice were treated 2 weeks after CT26 cell implantation (around 5 
mm of diameter). All mice were randomly allocated into 5 groups as follows: 
Group 1 (normal, n=7), group 2 (CT26 injected control, n=7), group 3 (CT26 
+ cisplatin, n=7), group 4 (CT26 + PD, n=7) and group 5 (CT26+ cisplatin 
and PD, n=7). PD (5 mg/kg) and cisplatin (5 mg/kg) were administered via 
oral and intraperitoneal route for 4 weeks, respectively. Normal and CT26 
injected control mice were treated with saline (0.9%). The body weight and 
the tumor volume were monitored 3 day interval. Tumor volume was 
measured by longest (length) and shortest (width) dimension using a dial 
caliper. Tumor volume was calculated by the following formula: tumor 
volume (mm3) = 0.52 × length (mm) × width (mm) × width (mm). At the 
end of the experiment, the surviving mice were sacrificed by cardiac 
puncture after being anaesthetized lightly with carbon dioxide. Blood was 
collected and serum was separated by centrifuging at the 800 g for 15 min, 
and the serum samples were subjected to biochemical examination. Liver 
and kidney samples were taken from each mouse for the biochemical 
examinations and stored at -70°C until analysis. The experimental protocols 
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were approved by the Institutional Animal Care and Use Committee of 
Chungnam National University (Daejeon, Korea). 
 
Determination of synergistic index 
In vivo synergism between cisplatin and PD was assessed using a relative 
ratio of tumor volume (RRTV) as a synergistic index (Dings et al., 2003). 
RRTV and expected relative ratio of the combination were calculated as 
follows; RRTV = mean tumor volume experimental/mean tumor volume 
control; Expected combination ratio = Mean RRTV of cisplatin × mean 
RRTV of PD.  
The synergistic index was obtained by dividing the expected relative ratio 
by the observed relative ratio. A synergistic index of >1 indicates a 
synergistic effect; an index of <1 indicates a less than additive effect.  
 
Serum biochemical examination 
The serum ALT, AST, CRE and BUN activities were determined on a dry 
chemistry system, the Vettest 8008 blood chemistry analyzer (IDEXX 
Laboratories, Westbrook, ME, USA). 
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Oxidative status in liver and kidney tissue 
After homogenate liver and kidney tissue, all assays were performed using 
commercially available kits according to the manufacturer’s protocols. The 
GSH level was determined using the improved DTNB [5,50-dithiobis-(2-
nitrobenzoic acid)] method. The SOD level was monitored using the 
tetrazolium salt. The levels of malondialdehyde (MDA), the terminal product 
of lipid peroxidation, were measured with the thiobarbituric acid reduction 
method. NO levels were measured by the improved Griess reaction method.  
 
Pharmacokinetic study 
Ten healthy male Sprague-Dawley (SD) rats (6-7 week, 180-200 g) were 
used in this study. All rats were randomly divided into two groups (n=5/each). 
The first group received 2 mg/kg of PD via intravenous (IV) route and the 
second group was treated with 35 mg/kg of PD using oral administration. 
Blood samples (0.2 mL) were collected from the tail-vein of SD rats into 
heparinized tubes at 0, 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 h after dosing. 
After centrifugation, the plasma samples (50 µL) were mixed with 10 µL of 
the internal standard (IS; dexamethasone, 20 μg/mL) and 90 µL of 
acetonitrile was then added for extraction. The mixture was vortexed for 10 
111 
min and then centrifugated at 1,200 g for 10 min. After centrifugation, the 
supernatant (10 μL) was injected into LC/MS. 
Extracted plasma samples were analysed on the Agilent 1100 series 
LC/MSD system. Separation was achieved on the XTerraMS® C18 reverse 
phase column (2.5μm, 3×50 mm, Waters, USA) at ambient temperature. The 
mobile phase consisted of 0. 1% formic acid in water (A) and 0.1% formic 
acid in acetonitrile (B) and the gradient flow was as follows: 20 % (v/v) B 
for 3 min, then increased to 100% B over 13 min, held for 3 min, then 
returned to initial condition 20% B and equilibrated for 5 min before the next 
injection. The flow rate was 0.4 mL/min. The electrospray ionization (ESI)-
MS analysis was performed on an Agilent 5989 mass spectrometer with an 
ESI interface fitted with a hexapole ion guide. The optimal condition for the 
analysis of PD and IS employed pneumatic nebulization with nitrogen (45 
p.s.i.) and a counterflow of nitrogen (9 L/min) heated to 350°C for the 
nebulization and desolvation of the introduced liquid. Mass spectrometer was 
performed using the negative ion mode and the selected ion monitoring 
(SIM), detecting at m/z 1224.3 for PD and m/z 391.4 for IS with a dwell time 




Statistical analysis  
Results were expressed as mean ± standard error (SEM). The significances 
of differences among experimental groups were determined using the one 
way analysis of variance (ANOVA) test or the non-parametric Kruskal-
Wallis test. Where significant effects were found, post hoc analysis using the 
Tukey’s multiple comparison test or Mann-Whitney U-test was performed 
and p<0.05 was considered to be statistically significant. 
 
Results 
In vitro study 
Synergism assay 
The viability of CT26 after PD and cisplatin treatment was shown in Fig. 1 
(A and B). The viability levels of CT26 cells decreased in a dose- and time-
dependent manner with increasing doses of both PD and cisplatin treatment. 
After 48 h of incubation, the viability of CT26 cells decreased from 91% to 
8.7% with increasing doses (3-22 μM) of the PD, from 98% to 0.1% with 
increasing dose (0.3-10 μM) of cisplatin. The half maximal inhibitory 
concentration (IC50) of cisplatin and PD were 1.22±0.10 and 8.21±0.51 μM, 
respectively, after 48 h incubation. To determine whether the combined 
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effects of the PD and cisplatin were synergistic, the CI value was calculated. 
The median effect plot, dose effect curve and fa-CI plot were shown in Fig. 1 
(C, D and E). The combination treatment showed higher dose-effect plot than 
that of single treated cells (Fig. 1 C and D). The fa-CI indicates that the PD 
and the cisplatin combination yielded synergistic effects with CI values 





Fig. 1. The effect of PD, cisplatin and its combination on CT26 cell viability. Cell viability 
was measured using resazurin assay. CT26 cells were treated with serial concentration of PD 
(A; 0, 3.0, 3.3, 5.5, 6.0, 6.5, 11.0, 12.0, 13.0, 22.0, 24.0 and 26.0 μM) and cisplatin (B; 0, 0.3, 
0.6, 1.2, 2.5, 5.0, 10.0 and 20.0 μM) for 24, 48 and 72 h. For combination assay, CT26 cells 
were incubated with PD (3.0, 3.3, 5.5, 6.0 and 6.5 μM), cisplatin (0.3, 0.6, 1.2, 2.5 and 5.0 
μM) and its 1 to 1 combined mixture for 48 h(C, D, E). 
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Cell cycle and apoptosis analysis 
The CT26 cells were treated with 20 μM of PD for 0, 24, 48 and 72 h. The 
cell population in sub-G1 was gradually increased after PD treatment in a 
time-dependent manner (Fig. 2). In addition, time-dependent decrement in 
the G0/G1 phase population (67%-24%) was observed as compared with a 
negative control (70%). However, significant cell-cycle arrest was not 
observed at all phases in different treatment (Table 1). 
To confirm PD induced apoptosis, Annexin V-FITC/PI double staining 
was conducted (Fig. 3). The CT26 cells were treated with different 
concentration of PD (0, 10, 20 and 40 μM) for 48 h. The apoptosis was 
induced in CT26 cells after exposure to 10 μM of PD (22.6%). In 20 μM of 
PD treated cells indicated 25.2% of early and late apoptosis (lower right and 
upper right quandrants). Some propidium iodide only stained cells were also 




Fig. 2. The effects of PD on CT26 cell cycle. The sub-G0/G1 apoptotic, G0/G1, S and G2/M 
phase of CT26 cells were quantified by flow-cytometry using propidium iodide stain. CT26 
cells were analysed after treatment of PD (20 μM) for 24, 48 and 72 h. 
 
 
Table 1. Effect of PD on cell cycle distribution in CT26 cells. 
 Control (%) 24 h(%) 48 h(%) 72 h(%) 
Sub G0/G1 2.0±1.0 3.2±1.0 11.5±1.5 49.8±2.2 
G0/G1 70.9±3.2 67.9±2.5 56.0±3.3 24.8±1.9 
S  11.1±2.1 12.2±2.4 13.1±2.1 15.2±3.2 
G2/M 16.0±0.9 16.7±0.7 19.2±1.1 10.0±0.5 
Cell cycle was analysed after treatment of PD (20 μM) for 24, 48 and 72 h using flow-





Fig. 3. PD induced apoptosis in CT26 cells. The apoptosis was measured by Annexin V-
FITC/ propidium iodide (PI) staining. CT26 cells were treated with 0 (A), 10 (B), 20 (C) and 
40 (D) μM of PD for 48 h, and analyzed with flow-cytometry. The horizontal and vertical 
axes represent labeling with annexin V-FITC and PI, respectively. Lower right represents 
early apoptotic cells, upper right represents late apoptotic cells. Lower left represents normal 
live cells and upper left represents necrotic cells. 
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Western blot analysis 
The CT26 cells were treated with 0, 20 and 40 μM of PD for 24, 48 and 72 
h. The protein expression levels were determined using Western blot analysis 
(Fig. 4). The phosphorylation of JNK and ERK were significantly increased 
after PD treatment compared to control cells. 
 
 
Fig. 4. The effect of PD on protein expression in the CT26 cell. The CT26 cells were treated 
with 0, 20 and 40 μM of PD for 24, 48 and 73 h. The protein expression levels were 




In vivo study 
Determination of synergistic index 
The combination effect of PD and cisplatin on the growth of CT26 in 
BALB/c mice was assessed (Fig. 5). Even though, the tumor volume was 
gradually increased in all group, tumor volume assay showed that either PD 
or cisplatin individually resulted in effective suppression of tumor growth 
with 59% and 43% of that in control mice at day 23, respectively. In 
combination treated mice showed significantly smaller tumor volume (30% 
of control mice) if compared to control mice. In table 2, the RRTV of the 






Fig. 5. Tumor volume in PD, cisplatin and combination treated mice (n=7/each group). Male 
Balb/c mice were transplanted subcutaneously with CT26 cells (2x105) into the right frank. 
The mice were treated 2 week after CT26 cell implantation. PD (5 mg/kg) and cisplatin (5 
mg/kg) were administered via oral and intraperitoneal route for 4 weeks, respectively. 
Normal and CT26 injected control mice were treated with saline (0.9%). Body weight and 
tumor volume was monitored 3 day interval. Tumor volume was measured by longest 
(length) and shortest (width) dimension using a dial caliper. Tumor volume was calculated 




Serum biochemical examination 
To assess liver and kidney function, serum enzymes were monitored in 
different treatment group. As shown in Fig. 6, only serum AST was 
significantly increased after CT26 transplantation. In addition, PD treated 
group showed similar serum enzyme levels compared with control group 
mice. In cisplatin alone treated group, cisplatin administration caused 
impairment in the liver and renal functions, as characterized by increase in 
all serum ALT, AST, BUN and CRE levels by 2.3, 1.1, 6.4 and 2.1 times than 
those in the control group, respectively (p < 0.05). Meanwhile, combination 
treated group showed mildly ameliorated serum enzyme levels in the ALT 




Fig. 6. Effect of cisplatin, PD and its combination therapy on serum ALT, AST, BUN and 
CRE in the CT26 tumor bearing mice (n=7/group). PD (5 mg/kg) and cisplatin (5 mg/kg) 
were administered via oral and intraperitoneal route for 4 weeks, respectively. Normal and 
CT26 injected control mice were treated with saline (0.9%). Values are expressed as means 
± SEM. ap<0.05, a significant difference when compared with the normal group. bp<0.05, a 
significant difference when compared with the control group. cp<0.05, a significant 
difference when compared with the group treated with the cisplatin treated group. 
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Evaluation of GSH, SOD, TBARS, and NO levels 
The CT26 cells transplanted control group mice showed similar oxidative 
status compared with normal group mice both in liver and kidney tissue, 
except NO value (Fig. 7). The NO value in control group was almost 4 times 
higher than that of normal group mice (p<0.05). The cisplatin alone 
treatment caused a decrease in the levels of GSH and SOD, but combination 
treated group showed restored antioxidant enzyme levels (p<0.05). 
Meanwhile, the level of TBARS increased in the cisplatin treated group 
compared with the level in the control group, while the combination 
treatment slightly reduced level of TBARS enzymes compared with the level 




Fig. 7. Effect of cisplatin, PD and its combination therapy on GSH, SOD, TBARS and NO 
in the CT26 tumor bearing mice (n=7/group). PD (5 mg/kg) and cisplatin (5 mg/kg) were 
administered via oral and intraperitoneal route for 4 weeks, respectively. Normal and CT26 
injected control mice were treated with saline (0.9%). Values are expressed as means ± 
SEMValues are expressed as means ± SEM. ap<0.05, a significant difference when 
compared with the normal group. bp<0.05, a significant difference when compared with the 
group treated with the control group. cp<0.05, a significant difference when compared with 




The mean time concentration curve for the rats given PD is shown in Fig. 
8. A non-compartmental model best fitted the plasma concentrations both in 
IV and PO group. As shown in table 2, the half-life of PD was 3.05±0.55 and 
3.34±0.01 h after IV and PO administration, respectively. After PO 
administration, PD reached 0.31±0.02 μg/mL of Cmax at 1 hafter 




Fig. 8. Mean plasma concentrations of PD vs. time curves in SD rat after IV (2 
mg/kg) and PO (35 mg/kg) administration (n=5/group). 
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Table 2. Main pharmacokinetic parameters of PD in the SD rat 
Parameters (unit) IV (2 mg/kg, n=5) PO (35 mg/kg, n=5) 
T
1/2λz
 (h) 3.05±0.55 3.34±0.01 
C0 (μg/mL) 13.78±2.79 -  
Tmax (h)  - 1 
Cmax (μg/mL)  - 0.31±0.02 
AUCINF (μg·h/mL) 8.69±1.58 1.60±0.088 
Vz (L/kg) 1.02±0.18 -  
Cl (L/kg/h) 0.23±0.06 -  
MRT (h) 2.78±0.43 5.03±0.05 
Vss (L/kg) 0.63±0.14 -  
F  (%)  - 0.991 
T1/2λz, half-life; C0, initial concentration; Tmax, time of peak; Cmax, peak plasma 
concentration; AUCINF, area under the plasma concentration-time curve from 0 to infinite; 
Vz, volume of distribution of the terminal phase; Cl, clearance of the terminal phase; MRT, 







Chemotherapy improves overall survival rate but the side effect of 
chemotherapy is a serious problem in cancer patients, thereby requiring a 
potent agent with a minimum side effect (Wang et al., 2008). Recently, there 
has been a growing interest in the cancer treatments using combined agents 
with distinct molecular mechanisms which exert higher efficacy with lower 
toxicity (Sarkar and Li, 2006). Natural compounds are generally recognized 
as a relatively non-toxic agent compared to the chemical compounds. Several 
natural compounds exhibit excellent preventive effect in chemotherapy-
induced toxicity with anti-oxidative effect (Block et al., 2007; Falsaperia et 
al., 2005; Wessner et al., 2007). In addition, it has been reported that the co-
administration of natural compounds with a cytotoxic chemotherapeutic 
agent exhibit synergistic effects with ameliorated side-effect (Lee et al., 2008; 
Sriganth and Premalatha, 1999). In the present study, we have evaluated the 
anticancer activity of PD, alone and in combination with cisplatin to explore 
its combination effect in vitro and in vivo. In vitro study, PD exhibited dose- 
and time-dependent growth inhibition effect in the CT26 cell by inducing 
apoptosis which was confirmed by flow-cytometry. Kim et al. (2008) 
reported that PD showed similar effects to that of paclitaxel, both of them 
causing mitotic arrest in the G2/M phase in human leukemia cells (Kim et al., 
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2008a). Recently, PD-induced apoptosis was observed in AGC human gastric 
cancer cells with markedly increased sub-G0/G1 ratio, a marker of apoptosis 
(Chun et al. 2013). In the present study, sub-G0/G1 phase of PD treated 
CT26 cells, even though different in cell type, also significantly increased 
after 72 h of incubation. Moreover, the combination of PD with cisplatin 
showed higher inhibition rate if compared to cisplatin alone treated CT26 
cells.  
In Western blot analysis, though the mechanism of PD-induced apoptosis 
is not fully elucidated, phosphorylation of JNK and ERK were increased in 
PD-treated CT26 cells compared to control cells. The JNK1 and JNK2 can 
act as either tumor promoter or suppressor kinases in different cancer types, 
thus the profile of both roles of JNKs in different tumors is responsible for 
the therapeutic potential of JNK inhibition (Bubici and Papa, 2014). It has 
been suggested that the JNKs suppresses tumor formation through their 
apoptotic functions which is connected with the mitochondrial pathway 
(Davis, 2000). Furthermore, Tournier et al. (2000) reported that murine 
embryonic fibroblasts lacking in JNKs showed resistance to the apoptosis, 
down-regulating pro-apoptotic molecules from mitochondria on UV 
irradiation. The ERK signaling pathway plays a crucial role in cell functions 
and mediates different anti-proliferative activity, including apoptosis, 
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autophagy and senescence, dependent on the cell type and the stimuli 
(Cagnol and Chambard, 2010). Furthermore, ERK has been reported to 
involve in cell death induced by various antitumor compounds, such as 
resveratrol and quercetin (Kim et al., 2008b; Shih et al., 2002).  
In vivo study, the mice from cisplatin alone and in combination with 
platycodin D treated group showed decreased body weights (about 76% of 
day 0). In CT26 cell transplanted control group, only serum AST level was 
significantly increased if compared to the normal group. AST is found not 
only in the liver as well as in many other organs such as heart, skeletal 
muscle, kidneys, brain, and red blood cells, the elevation in AST levels might 
derive from other organs as a result of cancer transplantation. In the present 
study, 4 weeks of cisplatin treatment leads to the increased serum enzymes, 
whereas combination treatment with PD decreased serum enzyme levels. 
Combination treatment showed synergistic effect on tumor volume growth 
inhibition as well as in vitro study,.  
The pathogenesis of cisplatin-induced tissue damage have mainly focused 
on the oxidative stress induced by direct toxicity of cisplatin (Santos et al., 
2008). Recently, it has been reported that natural compounds from plants 
with antioxidant capacity can attenuate the cisplatin-induced toxicity, such as 
quercetin, luteolin, and curcumin (Behling et al., 2006; Ilbey et al., 2009; 
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Kang et al., 2011). In addition, we reported that the PD ameliorated 
cisplatin-induced nephrotoxicity with recovered oxidative status (Kim et al, 
2012). In line with our previous study, consecutive cisplatin treatment 
increased the TBARS level, a marker for malondialdehyde which is an end 
product of lipid peroxidation in kidney and especially in liver tissues. 
Meanwhile, combination treatment with PD significantly suppressed the 
cisplatin derived increase in TBARS levels. In addition, the levels of NO in 
both liver and kidney were markedly increased after CT26 transplantation. 
Many studies reported that NO involves in carcinogenesis including 
initiation, promotion, progression, metastasis, and tumor microcirculation 
and angiogenesis (Fukumura and Jain; 1998; Lala and Orucevic, 1998; 
Thomsen and Miles, 1998). Combination treatment in this study decreased 
NO levels compared to both control and single cisplatin treated groups. 
Furthermore, combination treatment enhanced the levels of both GSH and 
SOD compared to the single cisplatin treated group, both of them being an 
essential antioxidant preventing reactive oxygen species derived cellular 
damage (Kaplowitz, 1981). 
Pharmacokinetic study was explored in SD rats after IV and PO 
administration of PD. The half-life was similar in both IV and PO 
administered rat, meanwhile, the oral bioavailability was significantly lower 
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with 0.9% value, indicating poor absorption of the compound. Interaction of 
herbal compounds with drugs could change its pharmacokinetic properties 
by altering its absorption, distribution, metabolism, or elimination of a 
conventional drug (Chavez et al., 2006). To expand possibility of the 
combination therapy in clinic, drug interaction in pharmacokinetic study 
between PD and cisplatin should be considered. 
In conclusion, PD treatment induces apoptosis in CT26 cells in dose- and 
time- dependent manner. In addition, the PD inhibits the growth of CT26 
cells and exerts synergistic effect with cisplatin in both in vitro and in vivo 
study. Moreover, combination treatment with PD attenuates cisplatin-induced 
oxidative stress. Further careful studies are requested to obtain safety profiles 
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The protective effect of PG against liver injury was assessed using 
chemical and surgical animal models. In chemical-induced hepatotoxicity 
study, PG produced hepato-protective effects against TA and CCl4-induced 
acute hepatic injury by decreasing the nitric oxide enzyme and lipid 
peroxidation. In addition, PG inhibited the HCV RNA replication with a 
35.46 of selective index (CC50/EC50) in Huh7 cells harbouring the HCV 
genotype 1b replicon. However, PG was unstable in simulated gastric juice. 
After incubation with gastric juice, digested PG showed poor hepato-
protective effect and decreased anti-HCV activity as compared to the intact 
PG. In surgical model, we used both acute and chronic BDL-induced 
cholestasis model. After 28 days of PG treatment, BDL-induced hepatic 
injury and fibrosis were decreased with recovered oxidative status and 
inhibited TGF-β1 expression.  
To confirm the phrmaceutical effect of saponin from Platycodon 
grandiflorum, PD was hired as a target compound. In the chronic BDL model, 
PD reduced oxidative stress and ameliorated apoptosis and tissue fibrosis in 
a cholestasis-induced hepatotoxic liver. Moreover, the expression of NF-κB 
and inducible nitric oxide synthase in the liver tissue were significantly 
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decreased after PD treatment. In cancer model study, PD treatment induces 
apoptosis in CT26 cells in dose- and time- dependent manner. In addition, 
the PD inhibits the growth of CT26 cells and exerts synergistic effect with 
cisplatin in both in vitro and in vivo study and combination treatment with 
PD attenuates cisplatin-induced oxidative stress. In this study, terpenoid 
saponin from Platycodon grandiflorum found to have pharmaceutical effect 
against various animal models. Further studies requested to secure safety 






In basic terms, inflammation is a protective reaction of the body against 
external and internal stimuli. In the acute phase, it serves to remove 
triggering agents in addition to restoring tissue following damage. However, 
if the inflammatory process becomes overwhelming, it results in pain 
through activation of nociceptors by various inflammatory mediators and 
eventually it can become life threatening and requiring of clinical 
intervention (Dubin and Patapoutian, 2010).  
The nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, 
fever and inflammation in various diseases. Although the properties of 
NSAIDs may vary slightly between the diverse classes and generations, the 
main mechanism of action involves inhibition of cyclo-oxygenase (COX) in 
various organs. COX is the enzyme that converts arachidonic acid (AA) to 
form prostanoids, which are essential biological mediators including 
prostaglandins (PG) and thromboxanes (TX). In 1990, two decades after the 
discovery of COX, it was revealed that COX exists as two isoforms, COX-1 
and COX-2 (Meek et al., 2010; Vonkeman and Laar, 2010). In brief, COX-1 
is a constitutive enzyme found in many organs under normal conditions, 
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while COX-2 is an enzyme up-regulated during inflammatory processes. 
Additionally in 2002, the third COX isoform (COX-3) was discovered. It is 
encoded by the same gene as COX-1, but COX-3, as a clinical target, is yet 
to be fully understood (Botting, 2003; Perrone et al., 2010).  
In general, COX-1 is thought to be beneficial to the body’s homeostasis 
with functions including maintenance of mucosal epithelium integrity, thus, 
its inhibition readily leads to gastric ulcers (Buvanendran, 2012). Inhibition 
of COX-2 only could decrease production of prostanoids such as PGE2 and 
PGI2 that are just involved in inflammatory and pathological processes, as 
well as ameliorate pain generation (Agarwal et al., 2009). Therefore, many 
clinical trials with NSAIDs focus on the selective inhibition of COX-2 
enzymes because of the superior safety profile resulting from the COX-1 
sparing effect. 
Nowadays, there is a growing interest in animal welfare. Owners consider 
their pets as members of their families. The changed breeding environment 
and extended life span of pets has meant that they are predisposed to an 
extended spectrum of diseases for which owners are demanding a higher 
level of care. These trends have been an impetus for the development of 
more effective and innovative veterinary therapies (Giorgi, 2012; Giorgi et 
al., 2012a; Giorgi and Yun, 2012). However, veterinarians still have a 
reduced drug armamentarium compared to their human counterparts, thus, 
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many studies have been conducted on the use of human medicine in the 
veterinary field (Giorgi et al., 2012b; Lavy et al., 2011). As use of selective 
COX-2 inhibitors (coxibs) became more prominent in human medicine, it 
followed that many selective inhibitors were introduced into clinical use for 
the veterinary market. Nowadays, many pharmaceutical companies have 
their own coxib drugs and some of these active ingredients have been 
recently launched on the veterinary market.  
However, animal species differences in factors such as the sensitivity and 
disposition of certain drugs could evoke unexpected results if they are used 
without any understanding of the drugs’ behaviour in the target species 
(Toutain et al., 1997; Giorgi et al., 2011; Martignoni et al., 2006). In addition, 
to the best of the Authors’ knowledge, the cardiovascular effects of coxibs 
during protracted therapy have not described in animals. In contrast, in the 
human field, coxibs have been reported to produce adverse effects on 
cardiovascular system such as thrombotic disorders including cerebral 
vascular events and myocardial infarction (Cairns, 2007; Batlouni, 2010). 
Furthermore, animals can be more sensitive to coxibs than humans due to 
differences in drug metabolism, absorption and enterohepatic recirculation 
(Bergh and Budsberg, 2005). For these reasons, knowing the 
pharmacological properties, pharmacokinetic/pharmacodynamic and safety 
profile of each drug is essential in order to use veterinary coxibs 
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appropriately. 
The coxibs are a subclass of NSAID which have a COX-1 sparing effects. 
Because of steric hindrance, the COX-1 active site is smaller than that of 
COX-2. The bulky structure of coxibs restricts their inhibition of COX-1 but 
allows for complete inhibition of the COX-2 pathway. The classification of 
NSAIDs is expressed as COX-2 selective, COX-2 specific, or COX-2 
preferential. This indicates the drug selectivity for COX-2 and it is 
determined through calculation of the inhibitory concentration (IC50) COX-
1:COX-2 ratio (Vane and Warner, 2000; Bergh and Budsberg, 2005). 
However, these ratios have not been fully quantified and ratios for the same 
compound can be inconsistent, as the assays used were considerably 
different (Livingston, 2000; Pairet and Ryn, 1998).  
Coxibs are regarded as a third generation of NSAIDs (Sternon, 2001). In 
the human field, several coxibs have been launched. The first to be launched 
were rofecoxib and celecoxib, these have been categorized as first generation. 
The newest active ingredients (valdecoxib, parecoxib, etoricoxib and 
lumiracoxib) have been classified as second generation and possess a 
stronger selectivity for the COX-2 enzyme inhibition (Stichtenoth, 2004; 
Andersohn et al., 2006). In veterinary medicine deracoxib (2002), firocoxib 
(2007), mavacoxib (2008) and robenacoxib (2009) have been introduced for 
animal use (Bergh and Budsberg, 2005). Recently, cimicoxib (2011) has also 
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been introduced for the veterinary market from the human field (Emmerich, 
2012). 
Deracoxib (Deramaxx®; Novartis) was the first coxib to be approved in 
veterinary medicine (Papich, 2008). Deracoxib contains a sulfonamide 
moiety. Chemically it is a 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-
1H-pyrazole-1-yl] benzenesulfonamide and its molecular weight is 397.38 
g/moL. Deracoxib is categorized as a diarylheterocycle drug, these exert a 
time-dependent pseudo-irreversible inhibition of COX-2 (Walker et al., 
2001). Deracoxib was initially approved for postoperative orthopedic pain in 
dogs at 3-4 mg/kg by oral (PO) daily dose for a maximum of 7 days. In 2003, 
deracoxib was also approved for chronic administration at a dosage of 1-2 
mg/kg PO once daily (Smith, 2003). 
In in vitro evaluations, among the coxibs, deracoxib was determined as a 
highly selective COX-2 inhibitor with a COX-1/COX-2 ratio of 1275 in 
purified enzymes assay (Gierse et al., 2002). However when tested using 
canine whole blood, the COX-1/COX-2 ratio was only 12 (McCann et al., 
2004). This inconsistency resulted from the different types of cells with 
different cell conditions being used in each assay (Vane and Botting, 1995). 
In another study using dogs, deracoxib showed the same degree of COX-1 
and COX-2 inhibition as carprofen (COX-2 preferential drug), despite a wide 
variation of COX-1/COX-2 inhibitory ratios between the two drugs being 
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found in in vitro assays (Sessions et al., 2005). These discordance results 
between in vivo and in vitro studies suggest that the in vitro results do not 
provide a quantitative measure of difference in efficacy or safety (Papich, 
2008). 
In the pharmacokinetic evaluation after oral administration of deracoxib 
(2~3 mg/kg) in dogs, deracoxib had a protein binding affinity of over 90%. It 
also underwent hepatic biotransformation with an elimination half-life of 3 h, 
using biliary excretion as a major excretion route (Smith, 2003). After high-
dose administration (8 mg/kg) however, a non-linear elimination has been 
shown: deracoxib loses its COX-2 selectivity and starts to inhibit COX-1 
also (DCT, 2003). The nonlinearity at high doses might result from saturation 
of the metabolizing enzymes. In other species treated with deracoxib 
including cats (1 mg/kg) and horses (1~2 mg/kg), a longer half-life (7.9 and 
12 h, respectively) than dogs was reported (Davis et al., 2011; Gassel et al., 
2006). In cats and horses the hepatic enzymes, which participate in 
biotransformation of deracoxib, may be present at lower concentrations than 
in dogs and might therefore be saturated at lower concentrations, which leads 
to the longer half-life (Davis et al., 2011). 
Clinical trials in dogs showed that deracoxib (1~2 mg/kg PO for 3 days) 
was able to reduce postoperative pain and inflammation after dental 
extraction surgery (Bienhoff et al., 2012). In addition, Millis et al. (2002) 
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reported that the administration of deracoxib (1, 3, or 10 mg/kg PO) was 
more effective in reducing pain associated with urate crystal-induced 
synovitis than carprofen (2.2 mg/kg PO). Deracoxib treatment also showed 
no significant adverse effects (Millis et al., 2002).  
After 28 days of once daily administration of deracoxib (1.6 mg/kg PO), it 
was shown to be safer than aspirin in regards to risk of gastric ulceration in 
healthy dogs (Sennello and Leib, 2006). In addition, long-term therapy of 
deracoxib for up to 6 months administered at the labeled dose, was found to 
be safe and well tolerated in dogs without any significant nephrotoxicity 
(Roberts et al., 2009). On the contrary, at higher than labeled doses or when 
given with other NSAIDs or corticosteroids, deracoxib has been found to 
cause gastrointestinal perforations in dogs (Lascelles et al., 2005). 
Even though there has been no significant instances of hypersensitivity 
reported thus far, the administration of sulfonamide coxibs in animals 
allergic to sulfonamides should be carefully considered. Indeed it might be 
likely a cross reaction with other sulfonamides such as antimicrobial or an 
evocation of hypersensitivity (Shapiro et al., 2003; Sanchez-Borges et al., 
2004; Bergh and Budsberg, 2005; Ayuso et al., 2013). The hypersensitivity 
of sulfonamide coxib such as deracoxib is yet to be confirmed.  
Firocoxib (Previcox®; Meriel) was developed specially for the veterinary 
field (for dogs and horses). It was found to be 350~430 fold more selective 
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for COX-2 than COX-1 in in vitro canine whole blood assays (McCann et al., 
2004). Chemically it is a 3-cyclopropymethoxy-5,5-dimethyl-4-[4-(methyl 
sulfonyl) phenyl]-2-(5H)-furanone and its molecular weight is 336.402 
g/moL. The drug was launched several years ago and in this short time, the 
pharmacokinetic properties of firocoxib in dogs and horses have already 
been well established (Kvaternick et al., 2007a; 2007b; Letendre et al., 2008). 
Firocoxib is available as a chewable tablet oral preparation which has been 
approved in the European Union for dogs at a once daily administration of 5 
mg/kg. In addition, firocoxib, as an oral paste was approved by FDA for the 
control of pain and inflammation associated with osteoarthritis in horses at 
0.1 mg/kg once daily (Kvaternick et al., 2007b). In dogs, following PO 
administration (5 mg/kg), firocoxib was well absorbed and eliminated by 
hepatic metabolism and fecal excretion with an elimination half-life of 8 h 
(Kvaternick et al., 2007a). Firocoxib in horses (0.1 mg/kg) showed a 
bioavailability of 79% and an elimination half-life of 30 and 34 h for oral 
and intravenous administration, respectively. Due to its lipophilic and non-
ionizable nature, firocoxib was widely distributed with a volume of 
distribution value of 1.7 L/kg after intravenous administration in horse. 
Firocoxib showed a longer half-life compared with other NSAIDs, such as 
phenylbutazone and flunixin meglumine (Kahn and Line, 2010; Kvaternick 
et al., 2007b). 
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A clinical study including 1,000 dogs treated for a 40-day period, reported 
that withdrawal rate due to development of gastrointestinal side effects was 
only 2.9%. Over 90% of investigators and owners rated improved clinical 
scores after firocoxib treatment (Ryan et al., 2006). In a long-term study over 
52 weeks of treatment, a slight increase in withdrawal rate (5.1%) was 
reported due to GI signs (Autefage et al., 2011). Steagall et al. (2007) 
evaluated the adverse effects of oral firocoxib in healthy dogs for 29 days 
and found that a dose of 5.3±0.34 mg kg-1 of firocoxib did not cause any 
adverse effects on the GI tract or serum biochemical variables and was well 
tolerated in terms of hematological signs including platelet aggregation and 
buccal mucosal bleeding time index (Steagall et al., 2007). Firocoxib was 
found to be effective in a 90 day long-term study performed on relatively 
geriatric dogs (over 7 years) affected by osteoarthritis. The side effects 
reported (minimal biochemical changes and diarrhea) were thought to be due 
to age-related deterioration in liver and renal functions (Joubert, 2009). 
Furthermore, in the sodium urate crystal-induced synovitis model, firocoxib 
treatment (5.3~6.49 mg/kg) resulted in reduced lameness and increased 
weight-bearing at both 3 and 7 h post-treatment, as compared with carprofen. 
Firocoxib efficacy was similar to dogs treated with vedaprofen but without 
any cardiovascular effects (Hazewinkel et al., 2008). 
However, in developmental toxicity studies firocoxib showed embryotoxic 
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and foetotoxic effects in both rats and rabbits, inducing a variety of 
malformations and anomalies. Consequently firocoxib, as with other coxibs, 
is contraindicated for use during pregnancy and lactation in dogs. 
Furthermore, firocoxib had a low safety margin in puppies compared to older 
dogs. Thus, like other drugs, its use in very young animals requires careful 
monitoring (EMEA, 2006). 
Mavacoxib (Trocoxil®; Pfizer) is a long acting coxib which has a chemical 
structure of 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
benzenesulfonamide, it has a molecular weight of 385 g/moL and it acts as a 
preferential rather than selective COX-2 inhibitor if compared with carprofen. 
It is approved for the treatment of canine osteoarthritis requiring long-term 
treatment between 1 and 7 months EMEA, 2008. Mavacoxib is produced in a 
diverse range of tablets (6, 20, 30, 75 and 90 mg) as an oral chewable form. 
Unlike other coxibs, mavacoxib is recommended for monthly administration 
at 2 mg/kg because of its long half-life. In order to achieve steady-state 
concentrations, it is recommended that mavacoxib is administered with a 2-
week interval between the first and second dose with monthly dosing 
thereafter. 
The pharmacokinetics profile of mavacoxib has been well described in 
Beagle dogs (Cox et al., 2010). It showed significant low clearance rate (2.7 
mL/h/kg) with a large volume of distribution (1.6 L⁄kg) in experimental 
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intravenous administration. Especially in terminal halflife, all PO treated 
Beagle dogs (n = 63) showed an average value of 16.6 days with individual 
values ranging from 7.9 to 38.8 days. The half-life differences between 
individuals should be considered as a significant factor in the use of this drug. 
In fact, in individuals demonstrating a poor elimination rate this drug could 
evoke cumulative side effects. Moreover, it has been reported that food 
intake significantly affects mavacoxib absorption. The administration of 
mavacoxib (4 mg/kg) in fasted and fed dogs resulted in a bioavailability of 
46.1 and 87.4% respectively. In field trials, mavacoxib showed a terminal 
elimination plasma half-life of 44 days in the target population, however 5% 
of dogs had an extended half-life of 80 days. In addition, most animals 
treated with 2 mg/kg, maintained trough plasma mavacoxib concentrations 
associated with efficacy (Cox et al., 2011). 
As the safety profile has not been established in reproductive toxicity, 
application of mavacoxib to pregnant or breeding animals should be avoided. 
Furthermore, this kind of drug, which has a long half-life, should be 
carefully handled because of the potential for prolonged exposure. 
Robenacoxib (Onsior®; Norvatis) is a coxib which has been developed 
solely for use in veterinary medicine and is the only approved coxib in cats 
available as a tablet as well as injectable form (King et al., 2009). It is 
recommended at a dose of 1~2 mg/kg once daily for both species. It has a 
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chemical structure of 5-ethyl-2-[(2, 3, 5, 6-tetrafluorophenyl)amino]-phenyl 
acetic acid and a molecular weight of 327.27. Robenacoxib is a weak acidic 
drug (pKa 4.7) which has high protein-binding affinity (>98% in dogs) (Jung 
et al., 2009). In the in vitro COX-2 selectivity comparative study in dogs 
with whole blood assay, the IC50 ratio (COX-1:COX-2) was highest in 
robenacoxib (128.8) when compared to other NSAID such as deracoxib 
(48.5), nimesulide (29.2) and meloxicam (7.3) (King et al., 2010). In cats, 
robenacoxib also showed more COX-2 selectiveness (32.2) compared with 
diclofenac (3.9) and meloxicam (2.7) (Schmid et al., 2010a). 
Previous studies have revealed its pharmacokinetic properties via different 
administration routes including, intravenous, subcutaneous and oral 
administration in the dog and cat (Jung et al., 2009; Pelligand et al., 2012). 
In dogs, robenacoxib showed good bioavailability after oral (84%) and 
subcutaneous (88%) administration with a short blood half-life of 1 h (Jung 
et al., 2009). In addition, Silber et al. (2010) revealed that robenacoxib 
remained longer in inflamed synovial joints than blood. The anatomically 
focused persistence of robenacoxib may be triggered by its weak acidity and 
high proteinbinding affinity. In an inflamed area, the blood supply is 
increased and pH has become mildly acidic. These alterations allow 
robenacoxib to enter cells more readily than under normal conditions. The 
ion-trapping due to the pH change slows release of the drug and as a result, 
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intracellular drug concentrations increase (Brune and Furst, 2007). 
In a clinical study, Schmid et al. (2010b) reported that SC injection of 
robenacoxib exerted analgesic and antiinflammatory effects in the urate 
synovitis model at dosages of 0.25-4 mg/kg without COX-1 inhibition 
(Schmid et al., 2010b). In comparison with carprofen, robenacoxib also 
demonstrated good efficacy in field trials when given once daily (Reymond 
et al., 2012). Furthermore, robenacoxib provided similar efficacy and 
tolerability to meloxicam in controlling perioperative pain and inflammation 
in dogs (Gruet et al., 2011). In cats after ovariohysterectomy surgery, SC 
injected robenacoxib (2 mg/kg) provided a greater analgesic effect for up to 
24 h compared to buprenorphine (Staffieri et al., 2013). According to the 
study from King et al. (2012), as expected, robenacoxib had an excellent 
safety profile in young healthy cats when administered at daily dosages up to 
10 mg/kg for 28 days and up to 20 mg/kg for 42 days (King et al., 2012). 
Also in dogs, robenacoxib showed high safety index without any relevant 
toxicity with daily dosages as high as 40 mg/kg for one month and 10 mg/kg 
for 6 months (King et al., 2011). This proven safety of robenacoxib may 
result from its high COX-2 selectivity and rapid central compartment 
clearance with longer residence at inflamed sites (King et al., 2012). 
However there is no data on reproductive toxicity and robenacoxib should 
not be used in pregnant or breeding animals. 
153 
Cimicoxib (Cimalgex®; Vetoquinol) is a novel imidazole derivative coxib 
and a highly selective COX-2 inhibitor, that has recently been launched 
(Emmerich, 2012). Chemically it is a 4-[4-Chloro-5-(3-fluoro-4-
methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide and its molecular 
weight is 381.809 g/moL. Although it was originally developed to treat 
depression and schizophrenia, this compound showed good oral activity 
when tested in experimental models of acute and chronic inflammation and 
pain (Haroon et al., 2012). After some years of human clinical studies on its 
anti-inflammatory and analgesic properties, cimicoxib was redirected from 
the human to the veterinary field.  
Cimicoxib is available as chewable oral tablets licensed for dogs as a once 
daily administration given at a dose of 2 mg/kg. Due to its recent release, 
there is very little published data available. Recently an analytical method for 
cimicoxib pharmacokinetic study has been published (Giorgi et al., 2013). 
Sorbera and Ramis (2004) found that cimicoxib was more metabolically 
stable than celecoxib. In humans, cimicoxib undergoes demethylation and a 
subsequent conjugation reaction, the demethylated metabolite of cimicoxib 
has been found to be inactive in both COX-1 and COX-2 activity assays. In 
rats after oral and i.v. administrations, biliary excretion was the major route 
of elimination. 70 and 30% of the Cimicoxib dose was excreted in the feces 
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and urine respectively. In Beagle dogs, the bioavailability was 75% 
following oral administration (1 mg/kg) with tmax of 2 h and t1/2 of 7 h. Like 
in rats, biliary/intestinal excretion was the major route of elimination in 
Beagle dogs and cimicoxib was extensively metabolized, as <0.2% 
unchanged drug was detected (Sorbera and Ramis, 2004). In an in vivo 
inflammatory acute pain model study, 10 h after administration (2 mg kg-1) 
the plasma concentrations were above a level of 100 ng Ml-1 (the EC50/IC50 
values varied between 216 and 452 ng/mL for different parameters) in six out 
of ten animals. At 24 h, the concentrations are lower than the stated 
EC50/IC50 values in all animals. Considering the estimated differences in 
bioavailability and correcting for non-linear PK, it appeared that the effect of 
cimicoxib lasted for approximately 10-14 h in the simulated inflammatory 
acute pain model EMEA, 2009. In addition, the noninferiority study where it 
was compared with firocoxib confirmed that cimicoxib reduced the clinical 
signs of disease including lameness, pain, locomotor disturbance and oedema 
in dogs with chronic osteoarthritis during the 90 days of the follow up study. 
Furthermore, compared with carprofen, cimicoxib was also effective in peri-
operative pain control in orthopaedic or soft tissue surgery during the first 24 
h after surgery (EMEA, 2009). 
In a 26 week tolerance study with Beagle dogs, it was demonstrated that 
adverse effects occur on the gastrointestinal tract and to a lesser extent the 
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kidney especially papillary necrosis at higher doses (10 mg/kg). However, 
there were no significant adverse signs in the recommended dose group (2 
mg/kg) and notably, there were no cardiovascular events. The reproductive 
toxicity study with rabbits however, revealed that the cimicoxib affects 
fertility and fetal development. Since there are no data in pregnant bitches, 
“caution” or “cimicoxib is contraindicated in” is needed in breeding, 
pregnant and lactating dogs (EMEA, 2009). 
Several studies are available in the literature for most of coxib drugs in 
veterinary field. Among the coxib drugs in veterinary field, however, 
cimicoxib has a few peer-reviewed study on the pharmacokinetic profiles, 
due to its recent release. The aim of this study was to ubderstand the 
pharmacokinetic features of cimicoxib in several animal species including 
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Chapter 1. Pharmacokinetic profiles of the novel COX-2 selective 
inhibitor cimicoxib in dogs 
 
Abstract 
Cimicoxib is a novel imidazole derivative that is a cyclo-oxygenase 
(COX)-2 selective non-steroidal anti-inflammatory drug and the latest COX-
2 selective inhibitor to be released for veterinary use. Currently there is 
limited information available on the pharmacokinetic (PK) properties of 
Cimicoxib. The aim of the current study was to evaluate the PK features of 
cimicoxib after administration of the recommended dose and after 
administration of a more variable dose rate in the form of the commercially 
available tablet. In addition, the effects of food intake on the PK properties 
were also evaluated. In the first study, five healthy Beagle dogs received 2 
mg/kg cimicoxib via the oral route following a period of fasting. The second 
study was conducted using six healthy Labrador retriever dogs which each 
received an 80 mg tablet (approximate dose 1.95-2.5 mg/kg) using a 
crossover design, both in the fasted and fed condition. The plasma 
concentrations of cimicoxib were detected by a validated HPLC method.  
No adverse effects were observed in any dogs during the experiment. The 
results from the PK analysis were similar between the studies, regardless of 
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precision of dose and fasted and fed conditions. The mean peak 
concentration of cimicoxib was 0.49 and 0.43 μg/mL under fasted and fed 
conditions, respectively. The mean half-life was about 3 h after all treatments. 
In addition, simulated multiple dosing data revealed that time over minimal 
effective concentration was similar after 1.95, 2.0 and 2.5 mg/kg dose 
administrations. These findings suggest that slight variation from the 
recommended dose should not alter the therapeutic outcome. In addition, 




For over a decade, osteoarthritis (OA) has been increasingly diagnosed in 
dogs (Moreau et al., 2005), mainly due to a more humanized life-style 
(Hoffman and Perkins, 2008). Domesticated dogs are now living longer and, 
as a result, are more susceptible to age-related diseases such as cancer, 
arthritis, metabolic disorders, and obesity. Fortunately, the veterinary drug 
market continues to grow (Giorgi, 2012; Hoffman and Perkins, 2008) 
although available drugs for the veterinarian remains quite small. 
Chronic pain management during inflammatory disease has become a 
priority in pets. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit 
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cyclooxygenase (COX) enzymes, preventing the conversion of arachidonic 
acid to various prostaglandins and thromboxanes. COX-1 is considered to be 
a housekeeping enzyme and COX-2 is best known for its local up-regulation 
by pro-inflammatory stimuli, by production of prostaglandins involved in 
inflammatory responses and in the spinal cord facilitating transduction of 
painful stimuli (Vardeh et al., 2009). The analgesic and anti-inflammatory 
activity of NSAIDs is thought to be predominantly mediated through COX-2 
inhibition (Seibert et al., 1994; Zhang et al., 1997). 
Due to the severe side effects often associated with chronic NSAID use, 
there has been a boost in research in COX-2 selective inhibitor (coxib) drugs 
in human and veterinary medicine. In the last decade, five different COX-2 
selective drugs have been launched on the veterinary market, namely, 
deracoxib (2002), firocoxib (2007), mavacoxib (2008), robenacoxib (2009) 
and the most recent, cimicoxib (2011). Several studies are available in the 
literature for most of these drugs (Autefage et al., 2011; Bienhoff et al., 2012; 
Hanson et al., 2006; Kim and Giorgi, 2013; Reymond et al., 2012), and also 
for COX-2 inhibitor drugs labelled for human use and applied to veterinary 
medicine (Giorgi et al., 2012). However, there has been no peer-reviewed 
study on the pharmacokinetic (PK) profiles of cimicoxib in the dog. Recently, 
an analytical method for cimicoxib detection in dog plasma has been 
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developed and used to determine PK profile for a single dog (Giorgi et al., 
2013). 
The objectives of this study were to determine the PK features of 
cimicoxib in healthy dogs after a single oral administration of (1) 2 mg/kg 
and (2) 80 mg to dogs in the fasting and fed state. 
 
Materials and methods 
Chemical and reagents 
Pure cimicoxib and parecoxib (internal standard) powders (both >99.0% 
purity) were donated by Vetoquinol and Pfizer, respectively. High 
performance liquid chromatography (HPLC) grade acetonitrile (ACN), 
methanol (MeOH), dichloromethane (CH2Cl2), and diethyl ether (Et2O) were 
purchased from Merck. Analytical grade trifluoroacetic acid (CF3COOH) 
was obtained from BDH. Sodium chloride (NaCl) and ammonium acetate 
(AcONH4) were purchased from Carlo Erba. Distilled water was produced 
by a Milli-Q Milli-pore Water System (Millipore). All other reagents and 
materials were of analytical grade and supplied from commercial sources. 
The LC mobile phases were filtered through 0.2 μm cellulose acetate 





Beagle and Labrador retriever dogs were used. Each dog was housed in a 
single 3m × 2 m box and acclimatized for a minimum of 1 week. The 
experiments, approved by the Lublin local Animal Research Ethical Board 
(54/2012), were performed in accordance with the European Regulation on 
Animal Welfare (Directive 2010/63/EU). 
 
Study 1. cimicoxib 2 mg/kg administration (precise dose) 
Five healthy male adult Beagles with a weight and age range of 9-12 kg 
and 4-5 years, respectively, were used. The animals were considered 
clinically healthy on the basis of a physical examination and complete 
haematological analyses. The dogs were given cimicoxib (Cimalgex, 
Vetoquinol) at a dose of 2 mg/kg orally, after 12 h of fasting overnight. Water 
was provided ad libitum. The tailored doses were prepared by carefully 
partitioning and weighing the marketed chewable tablet. 
A catheter was placed into the right cephalic vein to facilitate blood 
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sampling. Blood samples for PK analysis (2-3 mL) were collected at 
intervals of 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, and 24 h after cimicoxib 
administration, and placed in collection tubes containing lithium heparin. 
The blood samples were centrifuged at 400 g for 5 min within 30 min of 
collection. The harvested plasma was stored at -20°C and used within 14 
days of collection. 
 
Study 2. cimicoxib 80 mg/dog administration (variation on recommended 
dose) 
Six healthy male Labrador retriever dogs weighing 32-41 kg and ranging 
in age between 2 and 4 years were used in this study. The dogs were 
considered clinically healthy on the basis of a physical examination and 
complete haematological analyses. Animals were randomly (drawn from a 
box) assigned to two treatment groups, using an open, paired, single-dose, 
two treatment, two-period, crossover design. Each dog received a single dose 
of 80 mg/subject cimicoxib (Cimalgex, Vetoquinol). The first group (n = 3) 
received the treatment in the morning, after fasting for 12 h overnight. The 
second group (n = 3) was treated with a single dose of 80 mg/subject 
cimicoxib in the morning, 15 min after the dogs had been fed canned meat 
dog food (250 g) with oatmeal (200 g) in a 20 cm squared container. After a 
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wash-out period of 2 weeks the groups were reversed and the treatments 
repeated. A catheter was placed into the right cephalic vein to facilitate blood 
sampling. Both the collection times and the sample handling were as 
reported for Study 1.  
 
Chromatographic conditions 
The analysis procedure was performed according to Giorgi et al. (2013). 
Briefly, plasma samples (500 μL) were added to internal standard (100 μL, 5 
μg/mL) and 10% CF3COOH (100 μL). After vortexing for 30 s, NaCl (4 mg) 
was added and the samples were vortexed again. After vortexing, 600 μL of 
CH2Cl2:Et2O (3:7, v/v) were added, then the samples were vortexed (30 s), 
shaken (60 osc/min, 10 min) and centrifuged at 21,913 g (rotor radius 10 cm) 
for 10 min at 10 °C. The supernatant (400 μL) was collected in a separate 
snap cap vial. The organic phase was evaporated under a gentle stream of 
nitrogen and reconstituted with 200 μL of mobile phase. Twenty microlitres 
of this latter solution were injected onto the HPLC system which was 
coupled to a fluorescence detector (HPLC-FL). 
The plasma concentration of cimicoxib was determined by liquid 
chromatography (LC Jasco) consisting of a quaternary gradient system (PU 
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980 plus) and an in line multi-lambda fluorescence detector (FL 2020 plus). 
The chromatographic separation assay was performed with a Kinetex C18 
analytical column (100 mm × 4.6 mm inner diameter, 2.6 lm particle size; 
Phenomenex) preceded by a security guard column with the same stationary 
phase (Kinetex XB-C18; Phenomenex). The system was maintained at 25 °C. 
The mobile phase consisted of acetonitrile:buffer (10 mM AcONH4, adjusted 
to pH 4.5 with AcOH) (35:65, v/v) at a flow rate of 1 mL/min with isocratic 
mode. Excitation and emission wavelengths for analysis were set at 268 and 
430 nm, respectively. 
 
Quantification 
The calibration curve of peak area vs. concentration (0.01, 0.05, 0.1, 0.5 
and 1 μg/mL) of cimicoxib was plotted. Least squares regression parameters 
for the calibration curve were calculated, and the concentrations of the test 
samples were interpolated from the regression parameters. Sample 
concentrations were determined by linear regression, using the formula Y = 
aX + b, where Y = peak area, X = concentration of the standard in lg/mL, a = 
the slope of the curve and b = the intercept with Y axis. The correlation 
coefficient of the calibration curve was >0.99. The cimicoxib recovery was 
76 ± 5.6% with a coefficient of variation (CV) < 6.3%. The limit of 
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quantification was 25 ng/mL. The full method validation can be found 
elsewhere (Giorgi et al., 2013). 
 
PK evaluation 
The PK calculations were carried out using WinNonLin v 5.3.1 
(Pharsight). Maximum concentration (Cmax) of cimicoxib in plasma, and the 
time required to reach Cmax (Tmax) were predicted from the data. The area 
under the concentration/time curve (AUC0-∞) was calculated using the linear 
trapezoidal rule. According to Akaike value and to goodness of fit criteria, 
changes in plasma concentrations of cimicoxib were best described using the 
mono-compartmental analysis. The adequacy of the curve fitting was 
assessed by the correlation coefficient and standard error of the estimated 
parameters. 
 
Determination of cimicoxib dosage regimens 
Based on the PK analysis of pooled data, computer simulations 
(WinNonlin 5.3) were performed to compare the time above minimal 
effective concentration (MEC) after different oral doses (1.95, 2, and 2.5 





The PK data between groups were assessed using ANOVA with 
Bonferroni’s post hoc test. The results are reported as standard deviations of 
the mean values (±SD). All the analyses were conducted using GraphPad 




No visible adverse effects were observed in any dogs in either of the 
studies over the 24 h following drug administration.  
 
Study 1. cimicoxib 2 mg/kg administration (precise dose) 
The mean time concentration curve for the five Beagle dogs given 2 
mg/kg cimicoxib is shown in Fig. 1. After oral administration, cimicoxib 
concentrations were detectable in plasma for up to 24 h in 2/5 dogs. A mono-
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compartmental model best fitted the plasma concentrations. The Cmax and 
Tmax were 0.52 (0.30-0.78) μg/mL and 2.98 (1.80-4.16) h, respectively. The 
distribution and disposition half-lives were 1.75 (0.58-2.89) h and 2.97 
(2.68-3.43) h, respectively. Some variability in the PK parameters was shown. 
The complete mean PK parameters are reported in Table 1. 
 
 
Fig. 1. Mean plasma concentrations of cimicoxib vs. time curve in Beagle dogs (n = 5) 
following PO administration (2 mg/kg). Bars represent the standard deviations. 
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Table 1 
Main pharmacokinetic parameters of cimicoxib (2 mg/kg) in the Beagle dogs (n = 5) 
R2, correlation coefficient; K01_HL, distribution half-life; K10_HL, disposition half-life; Tmax, 
time of peak; Cmax, peak plasma concentration; V_F, volume of distribution of the terminal 
phase; CL_F, clearance of the terminal phase; AUC0-∞, area under the plasma concentration-
time curve from 0 to infinite. 
  
Parameters Unit Mean (Range) CV (%) 
R2  0.94 (0.92-0.99) 4.14 
K01_HL h 1.75 (0.58-2.89) 69.49 
K10_HL h 2.97 (2.68-3.43) 10.74 
Tmax h 2.98 (1.80-4.16) 40.51 
Cmax µg/mL 0.52 (0.30-0.78) 38.91 
V_F mL/kg 2177 (936-3148) 42.26 
CL_F mL/h/kg 495.9 (242.0-636.1) 35.38 
AUC0-∞ h*µg/mL 4.67 (3.14-8.26) 51.72 
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Study 2. cimicoxib 80 mg/dog administration (variation on recommended 
dose) 
The mean PK profiles of cimicoxib in fasted and fed states are shown in 
Fig. 2. cimicoxib concentrations were detectable in plasma for up to 24 h in 
3/6 dogs in both groups. Large intra- and inter-subject variability was noted. 
Four dogs showed individual PK profiles that were almost identical in the 
fasted and fed states, while two subjects demonstrated variations in their PK 
profiles that were influenced by fasted/fed status (Fig. 3). Overall the mean 
PK curves for fasted and fed status showed similar but not identical profiles 
and the difference was not significant. There was some variability with 
fasted/fed status reported for the PK parameters (Table 2) but, again, the 
differences were not significant. These parameters with the variable dose 
rates were not significantly different from the parameters computed in the 2 




Fig. 2. Mean plasma concentrations of cimicoxib vs. time curves in Labrador retriever dogs 
(n = 6) following PO administration (80 mg tablet/dog) after fasted (-○-) and fed (-●-) status. 
Bars represent the standard deviations. 
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Fig. 3. Individual plasma concentrations of cimicoxib vs. time curves in Labrador Retriever 
dogs following PO administration (80 mg tablet/dog) after fasted (-○-) and fed (-●-) status. 




Pharmacokinetic parameters following a single PO administrations of 80 mg tablet/dog of cimicoxib in Labrador Retriever dogs 
(n = 6) 
R2, correlation coefficient; K01_HL, distribution half-life; K10_HL, disposition half-life; Tmax, time of peak; Cmax, peak plasma concentration; 
V_F, volume of distribution of the terminal phase; CL_F, clearance of the terminal phase; AUC0-∞, area under the plasma concentration-time 
curve from 0 to infinite; CV, coefficient of variation. 
 Fasted   Fed  
Parameters Unit Mean (Range) CV (%)  Mean (Range) CV (%) 
R2  0.97 (0.94-0.99) 2.19  0.95 (0.90-0.98) 3.23 
K01_HL h 2.53 (0.97-3.98) 49.61  3.10 (0.39-4.71) 48.95 
K10_HL h 3.85 (1.71-5.41) 35.91  3.72 (2.68-4.71) 20.78 
Tmax h 4.14 (2.59-5.83) 30.75  4.62 (1.47-6.80) 40.56 
Cmax µg/mL 0.49 (0.31-0.61) 22.59  0.43 (0.29-0.81) 44.59 
V_F mL/kg 2087 (1604-2557) 18.59  2310 (1820-2726) 40.56 
CL_F mL/h/kg 413.9 (290.2-669.8) 35.67  441.5 (300.0-547.2) 19.77 
AUC0-∞ h*µg/mL 5.94 (3.40-7.64) 28.42  5.27 (4.05-6.49) 18.04 
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Determination of cimicoxib dosage regimens 
A compartmental open PK model was fitted to the pooled data from five 
fasting Beagle dogs, and the model was used to simulate the concentration vs. 
time profile for several dosage regimens after oral (PO) administration. The 
parameters of this average model were V_F, K01 and K10, which were 2177 ± 
920 (mL/kg), 0.63 ± 0.46 (1/h), and 0.23 ± 0.02 (1/h), respectively. 
Following simulations of PO administration of cimicoxib at a daily dose of 2 
mg/kg, plasma concentrations were greater than the assumed MEC value of 
0.2 μg/mL for approximately 8.4 h. Simulation of PO administration of 
cimicoxib at daily dose range of 1.95-2.5 mg/kg gave drug concentrations 




Fig. 4. Simulated concentration vs. time curves of cimicoxib after multiple once a day PO 
administrations at different doses. Each line indicates a different dose as follows: 1.95 
mg/kg (- - -), 2 mg/kg (—) and 2.5 mg/kg (-··-). The horizontal dashed line represents the 





Cimicoxib is a second generation, highly selective COX-2 inhibitor that 
exhibits promising anti-inflammatory and analgesic activity. It was 
developed originally as a treatment for depression and schizophrenia 
(Almansa et al., 2003) but showed oral activity comparable to other coxibs 
when tested in experimental models of acute and chronic inflammation and 
pain (Rigau et al., 2003; Sorbera and Ramis, 2004). After some years of 
clinical development as an antiinflammatory and analgesic agent in humans, 
cimicoxib has recently been launched on the market for veterinary use 
(Emmerich, 2012). It is reported to have poor solubility in water, is widely 
distributed throughout the body after oral administration and is eliminated 
mainly via the faeces (75%) following biliary excretion (EMA, 2011). 
In the present study, cimicoxib did not produce any apparent adverse 
clinical signs in our experimental dogs which is in agreement with the high 
safety margin with regard to cardiorespiratory, gastrointestinal and central 
nervous system side effects previously reported (Rigau et al., 2003). 
Additionally, a recent study fully investigated cimicoxib safety in dogs that 
were given 2 mg/kg/day for 6 days and cimicoxib did not show any 
difference in the incidence of adverse events compared with other drugs of 
the same class (Grandemange et al., 2013). The rationale for the two 
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experimental studies described here was that in its marketed form, the same 
dose of cimicoxib could be administered to a canine population with large 
variations in weight, breed, status conditions, etc. In order to investigate the 
extent of any influence of this variation, a specific dose (2 mg/kg) was 
administered to Beagle dogs, a relatively genetically homogeneous 
population, of similar ages, weights and life conditions. These results were 
compared to those generated using a more variable dog population and a 
more variable dose rate. Such an investigation is of value particularly for 
drugs used to treat pain and inflammation, as treatments are often long-term 
and can be intermittent; convenient application is important, therefore, as is a 
low incidence of side effects. 
Like other coxib drugs, cimicoxib is offered as an oral chewable tablet 
which allows owners to treat their pets themselves. Although the chewable 
tablet form has benefits in ease of administration, it has the disadvantage of 
not allowing precise dosing. With chewable tablets, exact dosing can only be 
achieved by splitting the tablets based on bodyweight, which can be a 
tedious and inaccurate process. Thus, it is common to treat animals in a 
range of weights with the same dose, achieving the approximate 
recommended dose. Our second study was designed to reflect the range in 
doses that dogs are likely to receive when their owners are administering the 
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treatment. Both the product information and a recent efficacy study 
(Grandemange et al., 2013) on cimicoxib recommend a daily dose of 2 
mg/kg and this dose was therefore selected for our PK study. 
In the 2 mg/kg Beagle study, cimicoxib had Tmax and K10_HL values of 
2.9 h for both parameters. Sorbera and Ramis (2004) reported that cimicoxib 
(1 mg/kg) administered PO to a single Beagle had a similar Tmax (2 h) but a 
longer K10_HL (7 h). This difference in half-life was also reported in the 
cimicoxib EMA report (2011), where the K10_HL of cimicoxib was around 
2.5-4 h, and over 8 h in Beagles with normal and slow metabolisms 
respectively (EMA, 2011). It was suggested that the cimicoxib dosage should 
be reduced in dogs with impaired liver function. 
For the second experiment, the dogs were selected based on a bodyweight 
of around 30-40 kg. Dogs within this range of bodyweight would receive 
small variations on the recommended dose when administered a whole tablet 
(80 mg). The results from the second study examining PK parameters that 
are likely to result after client administered treatment under fasting 
conditions are in close agreement with 2 mg/kg dose study 1 data. 
Approximate dosing and a different dog breed did not result in significant 
differences in PK parameters.  
The second experiment was also designed to examine the effect of 
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fed/fasted status on PK profile. It is well known that solid food decreases 
gastric emptying rate, but gastrointestinal motility increases in the presence 
of food. Delayed arrival of the drug at the small intestine, where most drug 
absorption occurs, might result in a delayed onset with reduced absorption 
rate. On the other hand, increased intestinal motility also might increase the 
rate of transit of the drug through the intestine (Welling, 1977). The type of 
food may also affect the absorption of lipophilic drugs with bile flow 
alteration. Bile acts as a surfactant for dissolution of lipophilic drugs and 
improves the fat intake increasing drug absorption. Moreover, the secretion 
of bile can be enhanced by a high fat diet (Dongowski et al., 2005). 
A previous study using celecoxib showed that food can affect the PK 
profile of that coxib drug. It was found that a high-fat diet increases 
absorption of the drug compared to fasted control animals and compared also 
to a low fat diet (Paulson et al., 2001). In the present study, however, the 
meal was of the type that would normally be given to dogs in order to 
simulate the real-life situation. The AUC0-∞ in both fasted and fed treatments 
was similar (P = 0.50). The lipid contents of the food might account for the 
similar results. The mean values of Tmax and absorption half-life in the fed 
group were slightly delayed compared to the fasted group and Cmax was 
slightly decreased in the fed group (P = 0.74). However, these small 
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differences between groups were not significant. The rate of cimicoxib 
absorption remained almost unchanged regardless of fed or fasted state. 
Cimicoxib showed values for clearance and volume of distribution of one-
half and three-times the values for robenacoxib, respectively (Jung et al., 
2009) but were of the same order of magnitude to firocoxib (EMA, 2005). 
Further studies are required to clarify if the drug can penetrate inflamed 
tissues or synovial fluid at therapeutic concentrations. 
Large differences have been found in both intra- and inter-subject PK 
profiles. A previous report revealed that polymorphism of one or both 
metabolizing enzymes (CYP2D6 and CYP2C19) in Beagles might be 
responsible for these variations (EMA, 2011). The CYP polymorphism might 
also have affected the dogs used in the present study and in part explain the 
inter-subject differences. However, the factors that evoked the intra-subject 
differences in two dogs (in study 2) are obscure and further studies will be 
needed to clarify this issue. 
The MEC assumed in this study (0.2 μg/mL) had previously been reported 
in dogs (EMA, 2011). The simulation of PO administration of cimicoxib at 
1.95, 2.00 and 2.50 mg/kg showed a drug plasma concentration over the 
MEC in the range 8.3-9.4 h. This value is shorter than the efficacy of 
cimicoxib reported in rats (10-14 h) for pain relief (EMA, 2011) and the 
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difference might result from different assessment methods. Indeed the drug 
plasma concentration over the MEC and the efficacy in pain relief come 
from PK and pharmacodynamic (PD) evaluations, respectively. It is well 
known that for NSAIDs drugs, PK and PD are not in phase, accounting for a 
large anticlockwise hysteric loop (Toutain and Lees, 2004). Moreover it is 
recognised that there may be some discrepancy between plasma 
concentration and actual effect at the receptor level (Toutain and Lees, 2004) 
which may explain the lower value in the present study. In addition, species 
difference (dog vs. rat) could have affected the results. Notably in clinical 
subjects, the PK-PD hysteresis could be larger than in healthy patients, and 
parameters, such as the onset time and time over the MEC, should be 
verified with proper PK-PD studies. 
In conclusion, the PK parameters of cimicoxib in dogs given precise (2 
mg/kg) and approximate doses (ca. 1.95-2.5 mg/kg) were similar. In addition, 
there were no significant differences in PK values between the fasted and fed 
condition. Further studies are now required to investigate the true analgesic 
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Chapter 2. The pharmacokinetics and ex vivo cyclooxygenase selectivity 
of cimicoxib in fasted and fed horses 
 
Abstract 
The aim of the present study was to evaluate pharmacokinetic and 
pharmacodynamic properties of cimicoxib, a novel selective 
cyclooxygenase-2 (COX-2) inhibitor, in fasted and fed horses. A pilot study 
was conducted through administration of cimicoxib intra-gastrically at 2 
mg/kg (canine clinical dose) to three fasted and three fed horses. The full-
scale study was an open, single-dose, two treatments, two-period, crossover 
design (n=6) with a 2 week interval before the cross over, an increased dose 
of 5 mg/kg was administered due to the low bioavailability shown in the 
pilot study. Following cimicoxib administration (5 mg/kg), the mean 
maximum plasma concentration was 0.16 ± 0.01 µg/mL and 0.14 ± 0.03 
µg/mL in fasted and fed groups, respectively. The higher dose led to higher 
peak plasma concentrations and AUC than in the pilot study, though the 
increment of increase was not proportional to the dose. The mean time to 
maximum plasma concentration was delayed in the fed group (5.91 ± 3.23 h) 
compared with the fasted group (3.25 ± 1.17 h) without significant difference 
(p=0.12). In the ex vivo pharmacodynamic assay, the mean maximal 
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inhibition rate of thromboxane B2 and prostaglandin E2 was about 60% and 
70% respectively, in both fasted and fed groups. In the present study, 
although the COX-2 selectivity of cimicoxib was not shown, relatively low 
blood drug concentration of cimicoxib exhibited good COX-1 and -2 
inhibitions in horses. Although further investigations are required, cimicoxib 
use in equine practice is not recommended. 
 
Introduction 
The molecule 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl] 
benzenesulfonamide (cimicoxib) was discovered in the early 2000’s. In the 
early stages of its development, this novel imidazole derivative drug was 
studied in the context of depression and schizophrenia treatment in humans 
(Almansa et al., 2003). After several years of research, the selective COX-2 
inhibiting effect of cimicoxib was revealed, and this active ingredient was 
developed as an anti-inflammatory and analgesic agent (Rigau et al., 2003; 
Sorbera and Ramis, 2004). Nowadays, it is the latest coxib drug to be 
approved for use in dogs and marketed in the veterinary field. 
Joint disease is a common clinical problem in the horse and over 60% of 
lameness is related to osteoarthritis (OA) which hampers their abilities to 
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race, labor,...etc (Caron and Genovese, 2003; Caron, 2011). OA can be 
triggered by various causes such as trauma and infection which may 
contribute to the degenerative process in the articular space by releasing 
enzymes, inflammatory mediators, and cytokines (McIlwraith, 1996). 
Medical treatment is usually the preferred option in equine OA. Many 
drug types can be used such as systemic nonsteroidal anti-inflammatory 
drugs (NSAIDs), intra-articular steroids, visco supplementation and 
chondroprotectants (Goodrich and Nixon, 2006).  
  The use of NSAIDs is common due to their well recognised anti-
inflammatory and analgesic effects. However, the use of some NSAIDs in 
horses can induce toxicity in the gastrointestinal or renal systems due to their 
non-selective inhibition of cyclooxygenase (COX) (Snow et al., 1979, 
Gunson and Soma, 1983). NSAIDs act by inhibiting both COX-1 and -2 
pathways to prevent the conversion of arachidonic acid to various 
prostaglandins and thromboxanes. The COX-1 enzyme is considered to be a 
housekeeping enzyme which is involved in normal physiologic processes 
and the COX-2 enzyme is regarded as one of the main targets in the 
inflammatory response (Hawkey, 2002). For these reasons, there has been an 
increase in research on COX-2 selective inhibitor drugs in the veterinary 
field. These drugs have a COX-1 sparing effect with a reduced incidence of 
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associated side effects. However, recent studies have shown that the COX-2 
inhibitors may increase the possibility of cardiovascular event in humans 
(Rao and Knaus, 2008). In addition there are some indications that PGE2 and 
PGI2 derived from COX-2 pathways can play a protective role pertaining the 
oxidative damage (Adderley and FitzGerald, 1999). In the last decade, 
several COX-2 selective drugs have been launched on the veterinary market 
including deracoxib, firocoxib, mavacoxib, robenacoxib and most recently 
cimicoxib (Autefage et al., 2011; Bienhoff et al., 2012; Reymond et al., 2012; 
Kim and Giorgi, 2013; Jeunesse et al., 2013). Among these coxib drugs, 
firocoxib is the only approved option for horse treatment. Due to the limited 
options currently available, there is a need for the testing of new drugs for 
use in horses. Moreover, there are no studies on the pharmacokinetic (PK) 
profiles of cimicoxib in horses in the veterinary literature, due to its recent 
release. The aim of the present study was to determine the PK features of 
cimicoxib in the horse and evaluate its suitability as a candidate for horse 
treatment using a pharmacodynamic (PD) study measuring the inhibition of 
the inflammatory mediator levels. 
 
Materials and methods 
Chemicals and reagents 
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The standard compound of cimicoxib and parecoxib (internal standard) 
powders (both > 99.0% purity) were donated by Vetoquinol (Bertinoro, IT) 
and Pfizer (Rome, IT), respectively. All other reagents and materials were of 
analytical grade from Merck. Lipopolysaccharide (LPS) was obtained from 
Sigma Aldrich. ELISA assay kits for prostaglandin E2 (PGE2) and 




Six clinically healthy mares (7-12 years, 430-570 kg) were used in the 
present study. The mares were previously determined to be clinically healthy 
on the basis of a physical examination and full haematological analyses. The 
study protocol was approved by the ethics committee of the University of 
Pisa (authorization n° 001 4896/2013) and transmitted to the Italian Ministry 
of Health. The full-scale study was preceded by a pilot study. For the pilot 
study, the animals were randomly assigned to two groups using six slips of 
paper marked with the numbers 1-6, selected blindly from a box. Each 
subject received 2 mg/kg cimicoxib (Cimalgex 80 mg/tablet, Vetoquinol) in 
the morning. The first group (n=3) was treated after fasting for 12 h 
overnight and the second group (n=3) received the drug 2 h after feeding. 
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Fed animals had a diet composed of a ground cereal mixture Equifioc 
(Molitoria Val di Serchio, IT) in the afternoon and alfalfa hay in the morning. 
The oral formulation of cimicoxib was given to all animals via nasogastric 
tube and consisted of split tablets in 500 mL of distilled water. After 
administration, the nasogastric tube was rinsed with 500 mL of distilled 
water to ensure complete delivery of the drug into the stomach. General 
physiological signs were assessed throughout the study (24 h) including 
blood pressure, heart rate, respiratory rate and body temperature. Findings of 
this study showed very low values in drug plasma concentrations, hence after 
a 2-week wash-out period, a full-scale study with a dose increment was 
performed. The animals were randomly allocated to two treatment groups, 
using an open, single-dose, two treatment, two-period, crossover design with 
a two week interval. All animals received 5 mg/kg of cimicoxib in the same 
manner as in the pilot study.  
Following aseptic preparation, synovial fluid was collected from the 
radiocarpal joint of the forelimb using aseptic arthrocentesis. To protect 
horses from excessive stress and joint damage, the collection was only 
performed two times for each horse (2 and 10 h or 4 and 24 h) after 
cimicoxib administration. The rational for these collection points was 
extrapolated from the PK of cimicoxib in dogs early reported (Kim et al., 
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2014a) 
At the beginning of the experiments, a catheter for blood collection was 
inserted into the right jugular vein and blood (10 mL) was collected at 0, 
0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h after cimicoxib 
administration. The blood sample for PK analysis was placed in a lithium 
heparin tube. The samples were then centrifuged at 400 g for 5 min within 30 
min of collection, and the harvested plasma was stored at -20 °C until 
analysis. For PD evaluation, an additional 10 mL of blood was collected at 0, 
1, 4, 10, and 24 h, split evenly and stored in a sodium heparin tube (PGE2) 
and non-heparinised glass tube (TXB2).  
 
Pharmacokinetic evaluation 
The Pharmacokinetic calculations were carried out using WinNonLin v 
5.3.1 (Pharsight Corp). Maximum concentration (Cmax) of cimicoxib in 
plasma, and the time required to reach Cmax (Tmax) were predicted from the 
data. The area under the concentration/time curve (AUClast) was calculated 
using the linear trapezoidal rule. The non-compartmental analysis was used 




The HPLC analysis was carried out based on the Giorgi et al. (2013) 
method. The analytical method was shortly validated as follows. The 
standard curve was evaluated in addition to nine quality control samples with 
three different concentrations for each series of analyses. The intra- and 
inter-day repeatability was measured as coefficient of variation and was 
lower than 8.1%, whereas accuracy, measured as closeness to the 
concentration added on the same replicates, was lower than 6.2%. The limits 
of detection (LOD) and quantification (LOQ) were determined using signal-
to-noise ratios of 3 and 10, respectively. These parameters resulted in 
concentrations of 0.5 ng/mL and 2 ng/mL, respectively. 
 
Pharmacodynamic assay 
The sample preparation was performed according to a previously 
described method (Giorgi et al., 2011). The non-heparinised whole blood (5 
mL) in glass tubes was incubated for 1 h in a water bath (37 °C) for TXB2 
production. Tubes were centrifuged at 400 g for 10 min at room temperature 
and the serum was stored at - 20 °C until analysis. For the PGE2 assay, 20 µL 
(1 mg/mL) of LPS was added to sodium-heparinised blood (2 mL) and 
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incubated at 37 °C for 24 h to simulate PGE2 production from mononuclear 
cells. In addition, PBS added to heparinised blood was used as a negative 
control. After the incubation, blood was centrifuged at 400 g for 10 min and 
a 100 µL aliquot of plasma was mixed with 400 µL of HPLC-grade MeOH 
to precipitate proteins. The mixture was centrifuged at 400 g for 10 min at 
room temperature; the supernatant was collected and stored at - 80 °C. 
TXB2 and PGE2 analysis were performed using a commercial ELISA kit 
(validated for horses) according to the manufacturer’s protocol. The samples 
were diluted 15-, and 25-fold for TXB2 and PGE2 respectively, using the 
assay buffer supplied with the kit. 
 
Statistical methods 
The Pharmacokinetic data between groups was assessed using the 
ANOVA for a crossover study. The results are reported as mean ± SD. All the 
analyses were conducted using GraphPad InStat v.5.0 (GraphPad Software). 
In all the experiments, differences were considered significant if the 





During the entire experiment, there were no visible adverse effects in any 
horses in either of the studies over the 24 h following drug administration. 
Physiological signs and parameters were normal. 
 
Pharmacokinetics 
The plasma concentrations of cimicoxib vs. time after intra-gastric 
administration of cimicoxib (2 mg/kg) in fasted and fed states are shown in 
Fig. 1. In both plots, there was an initial rapid absorption up to 2 h followed 
by a less rapid increase in concentration and the plasma concentrations of 
cimicoxib were detectable for up to 24 h. The peak concentration time was 
delayed about 5 h in the fed group compared to that of fasted group.  
A non-compartmental model was used to calculate PK parameters of 
cimicoxib plasma concentration after intra-gastric administration (2 mg/kg). 
The various PK parameters from both the fast and fed groups are 
summarised in table 1. There were no significant differences between the 
two treatment groups except in the Tmax value, though statistical significance 
was not found due to large individual variation. 
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Fig. 1. Mean plasma concentrations of cimicoxib vs. time curves in fasted (-○-, n=3) and fed 
(-●-, n=3) horses following intra-gastric administration of Cimalgex (2 mg⁄kg). Bars 





Pharmacokinetic parameters of cimicoxib (2 mg/kg) in fasted (n=3) and fed (n=3) 
horses 
Lambda_z, terminal phase rate constant; HL_Lambda_z, terminal half-life; Tmax, time of 
peak; Cmax, peak plasma concentration; AUClast, area under the plasma concentration-time 
curve up to the last measurable concentration; Vz_F, apparent volume of distribution; Cl_F, 
apparent plasma clearance; AUMClast, area under the moment curve computed to the last 




Mean ± SD 
Fasted Fed 
Lambda_z 1/h 0.18 ± 0.05 0.21 ± 0.03 
HL_Lambda_z h 4.12 ± 1.14 3.26 ± 0.57 
Tmax h 3.66 ± 0.81 6.66 ± 2.42 
Cmax µg/mL 0.12 ± 0.03 0.10 ± 0.01 
AUClast h*µg/mL 1.08 ± 0.13 1.15 ± 0.18 
Vz_F mL/kg 10436 ± 1683 8091 ± 1310 
Cl_F mL/h/kg 1812 ± 268 1747 ± 337 
AUMClast h*h*µg/mL 7.69 ± 1.21 9.07 ± 2.02 
MRTlast h 7.03 ± 0.37 7.76 ± 0.64 
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The mean time concentration curve of horses administered with 5 mg/kg 
cimicoxib is shown in Fig. 2. The concentration vs. time curve from the full-
scale study showed a similar tendency to the pilot study plot (Fig. 1). The 
peak concentration point was shifted to the right side in the fed group vs. the 
fasted group. The complete set of mean PK parameters from the full-scale 
study are reported in table 2. Similarly to the pilot study, some variability in 
the PK parameters was shown. A Cmax of 0.16 µg/mL at a Tmax of 3.25 h and 
a Cmax 0.14 µg/mL at a Tmax of 5.91 h were obtained from horses in fasted 
and fed conditions, respectively. In addition, fasted and fed groups showed 
similar AUClast values with a 5 - 6 h range of elimination half-life. 
In both the pilot and full-scale study, the concentration of cimicoxib in 
synovial fluid showed similar trends to plasma concentration. However, 
synovial fluid concentration of cimicoxib varied from that in the plasma at 




Pharmacokinetic parameters of cimicoxib (5 mg/kg) in fasted (n=6) and fed (n=6) 
horses 
Lambda_z, terminal phase rate constant; HL_Lambda_z, terminal half-life; Tmax, time of 
peak; Cmax, peak plasma concentration; AUClast, area under the plasma concentration-time 
curve up to the last measurable concentration; Vz_F, apparent volume of distribution; Cl_F, 
apparent plasma clearance; AUMClast, area under the moment curve computed to the last 





Mean ± SD 
Fasted Fed 
Lambda_z 1/h 0.12 ± 0.03 0.12 ± 0.02 
HL_Lambda_z h 5.96 ± 1.79 5.63 ± 1.01 
Tmax h 3.25 ± 1.17 5.91 ± 3.23 
Cmax µg/mL 0.16 ± 0.01 0.14 ± 0.03 
AUClast h*µg/mL 1.49 ± 0.60 1.61 ± 0.72 
Vz_F_obs mL/kg 33340 ± 21790 34243 ± 30186 
Cl_F_obs mL/h/kg 3879 ± 2225 4067 ± 3329 
AUMClast h*h*µg/mL 10.96 ± 5.77 13.22 ±7.07 
MRTlast h 6.85 ± 1.51 7.70 ± 1.48 
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Fig. 2. Mean plasma concentrations of cimicoxib vs. time curves in fasted (-○-, n=6) and fed 
(-●-, n=6) horses following intra-gastric administration of Cimalgex (5 mg⁄kg). Bars 
represent the standard deviations. 
 
 
Fig. 3. Mean synovial fluid concentrations of cimicoxib in fasted (-○-, n=6) and fed (-●-, 





The levels of TXB2 and PGE2 were evaluated in the 0, 1, 4, 10, and 24 h 
time point samples. The inhibition rate for both mediators showed different 
behavior. The inhibition rate of TXB2 was increased at 1 h and maintained up 
to 10 h after administration. Its mean maximal inhibition rate was 62.4 ± 
13.8% and 54.6 ± 15.4% in fasted and fed conditions, respectively, without 
significant difference (Fig. 4). On the other hand, the inhibition of PGE2 
gradually increased and reached a maximal value at 10 h after administration 




Fig. 4. Ex vivo analysis of TXB2 inhibition rate in fasted (-○-, n=6) and fed (-●-, n=6) horses 




Fig. 5. Ex vivo analysis of PGE2 inhibition rate in fasted (-○-, n=6) and fed (-●-, n=6) horses 





In the present study the PK and the ex vivo PD of cimicoxib in horses is 
reported for the first time. Cimicoxib did not show any apparent adverse 
clinical signs, even if administered at 2.5 times the recommended canine 
clinical dose. This was in line with a previous finding reporting the high 
safety margin of cimicoxib in the gastrointestinal, central nervous and 
cardiorespiratory systems (Rigau et al., 2003). 
At the beginning of the study horses were treated with 2 mg/kg cimicoxib. 
This dose was selected according to both the product information and a 
recent efficacy study on the recommend daily dose in dogs (Grandemange et 
al., 2013). 
An earlier study on dogs revealed that food in the form of canned meat did 
not affect absorption of cimicoxib (Kim et al., 2014a). In both the pilot and 
full-scale study, a delay was found when drug was given together with food 
in line with a previous study (Maitho et al., 1986). However the difference in 
Tmax values (in both pilot and full scale studies) but it was without 
statistical significances due to large inter-subject variation. The shift in Tmax 
might have resulted from the rough fibrous feed preventing tablet contact 
with gastric secretions. However, the fibrous content did not affect drug 
absorption which was determined by systemic exposure of drug, the AUC. 
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In the present study, following administration of cimicoxib at a dose of 2 
mg/kg to six healthy horses, the average half-life was 4 h. This half-life was 
similar to that of dogs (Kim et al., 2014a). However, the mean Cmax in 
horses was about 0.1 µg/mL, which is relatively low compared to that in 
dogs (0.4 µg/mL) administered with the same dose (Kim et al., 2014a). 
Moreover, the above mentioned Cmax from horses was only about 50% of 
the minimal effective concentration (MEC, 0.2 μg/mL) reported in dogs 
(EMA report, 2011). Because of this low blood drug concentration, the 
administered dose of cimicoxib was increased to 5 mg/kg after the 2 week 
wash-out period. The data from the full-scale study showed both increased 
Cmax and AUC values from those in the pilot study. However, these 
differences were not proportional to the increment of dose increase. Even 
with a dose that was 2.5 times higher (5 mg/kg), the horses did not achieve 
average plasma concentration levels as high as in dogs which indicates a 
relatively low bioavailability or a high plasma clearance. This trend was 
similar also in donkeys (Kim et al., 2014b). Concurrent experimental trials in 
dogs showed that the disposition of cimicoxib after an oral administration 
was not linear for doses ranging from 1 to 4 mg/kg due to the limited 
solubility of cimicoxib (Jeunesse et al., 2013). It is also in line with likely 
species differences: indeed drugs such as ampicillin and amoxicillin showed 
oral bioavailabilities of 0-1% and 5% in horses and 30% and 60-80% in dogs, 
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respectively (Ensink et al., 1992; Ensink et al., 1996; Kung et al., 1994; 
Schulze et al., 2005). Unfortunately cimicoxib is not sold as injectable 
formulation because of its poor water solubility. That did not allowed to 
perform an IV administration in order to assess its oral bioavailability. 
There are several possible explanations for the low plasma concentration 
of cimicoxib in horses. One reason might be high Cl/F value that reflects 
both clearance and bioavailability. The observed plasma clearance of the 
drug was much higher in the horses (1,812 mL/h/kg) compared to dogs 
(413.9 mL/h/kg) after the same treatment. According to an earlier report, 
cimicoxib is mainly eliminated via the faeces following processing via two 
major metabolic pathways, glucuronidation and demethylation (EMA report 
2011). The phase II reactions including glucuronidation, acetylation and 
sulfation showed large variations among species and the horse has been 
recognised as a species with a relatively high glucuronidating capacity 
(Toutain et al, 2010). In addition, equine gastric pH levels have been 
reported to be highly variable depending on region of the stomach, this might 
result in poor absorption (accounting for a low F) depending on the drug pKa 
value (Murray et al, 1989). The daily intake of highly fibrous feed could also 
affect the small intestinal wall grooves reducing the drug absorption in 
comparison to other animal species (Baggot and Brown, 1998). The 
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pharmaceutical formulation could also have affected the bioavailability. 
Indeed the administered cimicoxib tablets are formulated specifically for 
dogs (containing lactose monohydrate, povidone K25, crospovidone, sodium 
laurylsulfate, macrogol 400, sodium stearyl fumarate and pork liver powder) 
which might have reduced the drug absorption in the horse. It is conceivable 
that different dissolution in the equine stomach may be responsible for any 
differences between the dog and horse for systemic availability of cimicoxib 
and variability in absorption following oral administration. However, 
additional studies on the dissolution of these tablets (designed for dogs) in 
equine gastric fluid might clarify a consistent and timely release of the active 
ingredient. 
The scientific literature contains many reports of in vitro studies 
undertaken to determine the potency of a wide range of NSAIDs as inhibitors 
of COX isoforms. As discussed earlier (Lees et al., 2004; Warner et al. 1999), 
assay results are markedly dependent on experimental conditions, such as 
isolated enzymes, broken cell vs. intact cell assays, and diverse buffer 
solutions, and intact cell whole blood assays have yielded very disparate 
findings. Most investigators conducting in vitro assays have preferred to use 
whole blood, on the grounds of greatest physiological relevance. Such assays 
use a matrix which is a natural body fluid containing both platelets and 
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leucocytes and accounts for the very high degree of drug binding to plasma 
protein, which characterises the great majority of NSAIDs (Pairet and Van 
Ryn, 1998; Young et al., 1996). However, even optimised in vitro blood 
assays can yield differing ratios to those obtained ex vivo and in vivo for 
individual drugs. Indeed in this study, ex vivo assays were used to determine 
TXB2 and PGE2 inhibition, these are representative parameters for the COX-
1 and COX-2 pathway respectively. 
Although the Cmax is often lower than the MEC (from dog, 0.2 µg/mL), 
the 5 mg/kg administered to horses resulted in a PGE2 inhibition rate of over 
70%. A diverse plasma protein binding between the animal species might 
have triggered this difference. However, the tendency of inhibition rate vs. 
time plots was not in phase with the concentration vs. time curve. The time 
of maximal effect was observed about 6 h later than peak concentration time. 
The drug blood concentration at certain points cannot be directly correlated 
to effect, due to the time interval between Tmax (PK) and the maximal 
inhibition time point (PD). This is in line with most NSAIDs drugs which 
have been found to show a large anti-clockwise hysteresis PK-PD loop 
(Pleuvry, 2005; Torres-López et al., 1997; Toutain, 2002). The PK and PD 
are not in phase due to a hysteresis between plasma concentration and actual 
effect at the receptor level (Toutain and Lee, 2004). This can also occur for 
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drugs such as aspirin, phenylbutazone and tepoxalin, which are converted to 
active metabolites in vivo (Lees et al., 2004).  
Unfortunately, TXB2 was also inhibited by cimicoxib treatment but with a 
rate and trend that was different to that of PGE2. The inhibition rate was 
lower than that of PGE2 and the TXB2 peak inhibition was found at 1 h after 
cimicoxib administration. The reason for the time interval between COX-1 
and -2 inhibition is obscure. Although dual inhibition of the COX isoforms in 
unexpected in a molecule classified as coxib, it is important to point out that 
the term “coxib” is used to denote a class of molecules possessing a tricyclic 
ring and a methyl-sulfonic group, and it is often improperly associated with 
COX-2 selective inhibition. The coxib class also includes molecules with 
COX-1 selective inhibition such as the experimental compound SC-560 
(Teng et al., 2003).  
The animal species might have played a role in determining COX 
selectivity. Indeed it is not the first time that an anti-inflammatory drug is 
selective in one animal species and non-selective in others. Hence, the lack 
of selectivity might be due to the animal species being treated. Similar 
results have been shown for carprofen, although carprofen has not a coxib 
structure. According to Lee et al. (2004), carprofen may act as a non-
selective drug in the horse rather than being a COX-2 preferential or 
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selective drug as it is in both the dog and cat. Meanwhile, from the previous 
report, phenylbutazone has a relatively high potency in horses compared to 
other species including dogs and humans (Gierse et al., 2002; Higgins and 
Lees, 1983). Further studies to assess the selectivity of cimicoxib in horses 
are required. It is noteworthy that cimicoxib, even though its maximal 
plasma level was below the IC50 reported in dogs, has revealed a good 
activity against the markers for inflammation and pain in the horse. 
  In conclusion, cimicoxib pharmacokinetics were characterised by low 
plasma concentrations and further studies are needed to clarify this behavior. 
Although the drug plasma concentration required to inhibit the COX 
enzymes was lower than the one reported in dogs, cimicoxib was found to be 
not COX-2 selective in the horse. At the light of these preliminary findings 
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Cimicoxib is a novel cyclooxygenase 2 inhibitor drug approved for use in 
dogs. Assessing pharmacokinetic profiles in target species is pivotal for 
extra-label applications. The purpose of the present study was to evaluate the 
pharmacokinetic profiles of cimicoxib after intragastric administration in six 
healthy jennies. Plasma concentrations of cimicoxib were determined by 
high performance liquid chromatography with fluorescence detector. A pilot 
study was carried out with two animal groups (n = 3) in fasted or fed 
conditions receiving 2 mg/kg of cimicoxib. Because of the relatively low 
Cmax (0.03 μg/mL) from the pilot study, the dose was increased (5 mg/kg) 
for the subsequent full-scale crossover study. Single administration of 5 
mg/kg did not show any adverse effects. However, the Cmax (0.02 μg/mL) 
and area under the curve (0.14 h × mg/mL) values obtained after 5 mg/kg 
administration were not dose dependent compared with those in the 2 mg/kg 
pilot study. The results from this study could provide basic but essential 
information for the use of cimicoxib. Further pharmacodynamic studies are 





Pain due to inflammatory processes is frequently a problem in equids. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) block pathologic processes 
by inhibiting cyclooxygenase (COX) enzymes. There is a trend for the 
replacement of NSAIDs with selective COX-2 inhibitors in treatment 
protocols to reduce the gastrointestinal and/or platelet disorders triggered by 
COX-1 inhibition (Kim et al., 2013). Cimicoxib is a recently marketed 
selective COX-2 inhibitor drug for use in dogs (Anonymus, 2012). Because 
of its recent release, there are little background data in other species. There is 
a particular need for broadening of the veterinaryarmamentarium of 
diagnostics and treatments, especially the range of available drugs for use in 
different diseases and/or animal species. This was the impetus for evaluation 
of the extra-label application of coxib drugs in species such as horses and 
donkeys (Kvaternick et al.,2007 ). 
Understanding pharmacokinetic (PK) properties is the first step in 
investigating the use of a particular drug in anew species. Few drugs used in 
donkeys have dosages based on evidence (Coakley et al., 1999; Matthews et 
al., 2001; Sinclair et al., 2006); most dosages are extrapolated from other 
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species (commonly horses). Thus, the aim of this study was to determine the 
PK properties of cimicoxib in donkeys. 
 
Materials and methods 
Animal study 
The animal experiment was approved by the ethics committee for animal 
welfare of the University of Pisa (protocol number 001 4896/2013). In the 
present study, six healthy jennies (6-9 years and 280-320 kg) were treated 
with two doses (2 and 5 mg/kg) of cimicoxib. 
For the pilot study, a 2 mg/kg dose was administered based on the clinical 
dose in dogs (Anonymus, 2011). The animals were randomly assigned to two 
groups. The first group (n = 3) was treated after fasting for 12 h overnight 
and the second group (n = 3) received the drug 2 h after feeding. Oral 
formulation of cimicoxib (Cimalgex 80 mg; Vetoquinol, Lure, France) was 
ground into powder and suspended in 200 mL of distilled water (DW). The 
suspension was given to all donkeys via a nasogastric tube. After 
administration, the nasogastric tube was rinsed with 500 mL of DW to 
complete administration into the stomach. Before administration, a catheter 
was inserted into the right jugular vein and blood (5 mL) was collected at 0, 
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0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h after cimicoxib 
administration. After a 2-week washout period, a second study was 
conducted with an increased dose of 5 mg/kg using an open, single dose, two 
treatments, two periods, and crossover design with 2 weeks of interval. The 
rationale for the increased dose was the low average cimicoxib plasma 
concentrations detected after the 2 mg/kg treatment. The jennies were treated 
in the same manner as the pilot study. 
 
Pharmacokinetic analysis 
Plasma concentrations of cimicoxib were determined by high performance 
liquid chromatography (HPLC) with fluorescence detector, as described 
elsewhere with slight modification (Giorgi et al., 2013). An extraction 
solvent composed by C2H2:Et2O (1:1, vol/vol) rather than C2H2:Et2O (3:7, 
vol/vol) was found to give a better cimicoxib recovery in plasma from 
donkey. The method was validated for plasma of jennies. The standard curve 
for analysis was linear from 0.01 to 2.5 mg/mL. The intra- and inter-day 
repeatability was < 6.9%, whereas accuracy was < 7.4%. The limits of 
detection and limits of quantification (LOQ) were 3 and 10 ng/mL, 
respectively. 
Each donkey was analyzed singularly using the PK software WinNonlin 
5.3 (Pharsight, St. Louis, MO). Donkeys having the same treatment were 
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grouped and averaged. Non-compartmental PK analysis was chosen as the 




The Pharmacokinetic data between groups was assessed using the 
ANOVA for a crossover study. The results are reported as mean ± SD. All the 
analyses were conducted using GraphPad InStat v.5.0 (GraphPad Software). 
In all the experiments, differences were considered significant if the 





There were no adverse effects observed at any point during the study. The 
plasma concentrations of cimicoxib were below the limit of quantification 10 
h after both the 2 and 5 mg/kg administrations (Fig. 1). There was no 
significant difference in PK profiles between the fasted and fed conditions in 
both the 2 and 5 mg/kg treated groups (Table 1). 
 
 
Fig. 1. Mean plasma concentrations of cimicoxib versus time curve in donkeys after 
intragastric administration of (A) 2 mg/kg (n = 3) and (B) 5 mg/kg (n = 6) after fasted (open 




Pharmacokinetic parameters of cimicoxib (2 mg/kg) in the donkey (n=6) 
AUClast, area under the plasma concentration-time curve up to the last measurable concentration; AUMClast, area under the moment curve 
computed to the last observation; Cmax, peak plasma concentration; Cl_F, systemic clearance per fraction adsorbed; HL_Lambda_z, terminal 
half-life; Lambda_z, terminal phase rate constant; MRTlast, mean residence time based on values up to the last measured concentration; R2, 
correlation coefficient; Tmax, time of peak; Vz_F, volume of distribution per fraction adsorbed. 
Parameters Unit 
2 mg/kg (n = 3) 5 mg/kg (n = 6) 
Fasted Fed Fasted Fed 
R2  0.92±0.051 0.96±0.015 0.90±0.034 0.80±0.137 
Lambda_z 1/h 0.29±0.129 0.26±0.216 0.19±0.153 0.13±0.065 
HL_Lambda_z h 2.72±1.391 5.17±5.385 5.28±3.494 5.89±2.486 
Tmax h 1.66±2.020 1.55±0.500 1.00±0.433 1.66±0.577 
Cmax µg/mL 0.03±0.003 0.03±0.009 0.02±0.005 0.02±0.004 
AUClast h*µg/mL 0.13±0.045 0.10±0.020 0.14±0.056 0.15±0.034 
Vz_F_obs mL/kg 46639±8379.2 75051±43458.8 175005±18814 195300±69291 
Cl_F_obs mL/h/kg 13861±7147 13828±6435 32402±22358 24440±7648.0 
AUMClast h*h*µg/mL 0.45±0.225 0.36±0.078 0.58±0.348 0.65±0.183 
MRTlast h 3.11±0.808 3.33±0.448 3.90±0.929 4.29±0.328 
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Discussion 
The 2 mg/kg treated group showed a low Cmax value and the Cmax was 
achieved more rapidly than that in dogs administered with the same dose (0.5 
mg/mL at 3 h) (Kim et al., 2014). According to the analysis of variance test 
for a crossover study, higher clearance (Cl_F) of cimicoxib was observed in 
donkeys (13,861 mL/h/kg) compared with dogs (495 mL/h/kg) (Kim et al., 
2014) and horses (1,812 mL/h/kg) (Kim et al., under review). In addition, the 
volume of distribution (Vz_F) of cimicoxib in donkeys was 46,639 mL/kg, 
which was 20 times higher than that of dogs (Kim et al., 2014). However, as 
clearance and volume of distribution after oral administration are linked to 
the functional dose (F), the different bioavailability of the drug in these 
animal species could have affected these two parameters.  
A previous study reported that oral cimicoxib at 2 mg/kg showed similar 
efficacy and tolerability compared with carprofen in dogs (Grandemange at 
al., 2013). However, the present PK study reports lower average cimicoxib 
plasma concentration and AUC values (>20 fold) than those reported in dogs. 
In the 5 mg/kg treated group, although the dosewas increased 2.5 times, the 
Cmax (0.02 mg/mL) was not significantly different than that obtained from 
the 2 mg/kg treated donkeys. The minimal effective concentration of 
cimicoxib in dogs has been reported to be 0.2 mg/mL (Anonymus, 2011). It 
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is unlikely that the drug plasma concentrations achieved in this study would 
produce pain relief in donkeys.  
Cimicoxb showed a small average area under the curve (AUC) value after 
intragastric administration in donkeys. In addition, drug distribution and 
elimination differed from that reported for horses (Kim et al., under review). 
Most of the PK parameters correlated with absorption and AUC was 
relatively low compared with that in horses. This trend has previously been 
reported for many other NSAID drugs such as phenylbutazone, flunixine 
meglumine, and meloxicam (Coakley et al., 1999; Matthews et al., 2001; 
Sinclair et al., 2006). Additionally, in the 5 mg/kg treated donkeys of the 
present study, the AUC and mean residual time (MRT) values were 
respectively 10 and 2 times lower than the AUC and MRT obtained from 
horses administered with 5 mg/kg of cimicoxib (1.5 h × mg/mL and 7 h) 
(Kim et al., under review). The short MRT might be indicative of a 
substantial first-pass metabolism and true higher clearance, but the IV 
administration is required to clarify this issue. Unfortunately, slight water 
solubility of the drug did not enable us to test cimicoxib after IV route. In 
fact, no IV pharmaceutical formulation of cimicoxib is present on the market. 
Differences in pharmacokinetics between horses and donkeys, although 
they are genetically related, may derive from different physiological 
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properties, which can affect absorption and distribution of the drug into the 
body system (Grosenbaugh et al., 2011). Donkeys are known to be desert-
adapted animals and can maintain blood volume and function even when 20% 
dehydrated, demonstrating a different fluid balance and body water 
compartment partitioning compared with horses (Yousef  et al., 1970). In 
addition, hepatic metabolism in donkeys has been shown to be more rapid 
with respect to horses for various drugs (Lees et al., 2004; Matthews et al., 
1997; Mealey et al., 1997). This study proved that interspecies variations can 
affect the pharmacokinetics of cimicoxib. These differences should be 
considered when extrapolating data from certain species to others (Giorgi , 
2012). 
In conclusion, a single administration of cimicoxib did not evoke any 
adverse effects even at doses as high as 5 mg/kg. However, after intragastric 
administration, cimicoxib drug plasma concentrations were low. Further 
pharmacodynamic studies are required to assess the efficacy of cimicoxib at 
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The drug must be explored carefully based on a species differences to 
secure its safe and effective clinical application. In dogs, the 
pharmacokinetic parameters in precise and approximate doses were similar 
in both fast and fed conditions. In horses and donkeys, the average serum 
concentration of cimicoxib was lower than that of dogs after the same dosage 
administration. In addition, cimicoxib was found to be not COX-2 selective 
in the horse. It is complicated work to make firm distinctions between 
preferential and selective COX inhibition or between nonselective and 
preferential inhibition. This is because 1. Potency ratios (COX-1:COX-2) 
vary widely according to experimental conditions both within and between 
laboratories, 2. the ratio calculated may vary depending on whether it is 
based on 50, 80, 95 or some other percentage inhibition and 3. apparent 
species differences in inhibition ratios. Further in vivo studies with diverse 
end-points are requested to obtain optimal clinical dosage regimens in 
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